



Risks and benefits of consuming edible seaweeds

Cherry, P., O'Hara, C., Magee, P., McSorley, E. M., & Allsopp, P. J. (2019). Risks and benefits of consuming edible seaweeds. *Nutrition Reviews*, 77(5), 307-329. <https://doi.org/10.1093/nutrit/nuy066>

[Link to publication record in Ulster University Research Portal](#)

Published in:
Nutrition Reviews

Publication Status:
Published (in print/issue): 01/05/2019

DOI:
[10.1093/nutrit/nuy066](https://doi.org/10.1093/nutrit/nuy066)

Document Version
Publisher's PDF, also known as Version of record

General rights
Copyright for the publications made accessible via Ulster University's Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Ulster University's institutional repository that provides access to Ulster's research outputs. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact pure-support@ulster.ac.uk.

Risks and benefits of consuming edible seaweeds

Paul Cherry, Cathal O'Hara, Pamela J. Magee, Emeir M. McSorley, and Philip J. Allsopp

Recent interest in seaweeds as a source of macronutrients, micronutrients, and bioactive components has highlighted prospective applications within the functional food and nutraceutical industries, with impetus toward the alleviation of risk factors associated with noncommunicable diseases such as obesity, type 2 diabetes, and cardiovascular disease. This narrative review summarizes the nutritional composition of edible seaweeds; evaluates the evidence regarding the health benefits of whole seaweeds, extracted bioactive components, and seaweed-based food products in humans; and assesses the potential adverse effects of edible seaweeds, including those related to ingestion of excess iodine and arsenic. If the potential functional food and nutraceutical applications of seaweeds are to be realized, more evidence from human intervention studies is needed to evaluate the nutritional benefits of seaweeds and the efficacy of their purported bioactive components. Mechanistic evidence, in particular, is imperative to substantiate health claims.

INTRODUCTION

Edible seaweeds (macroalgae) have the potential to provide a rich and sustainable source of macronutrients and micronutrients to the human diet, particularly in regions where seaweed makes a significant contribution to regular meals, eg, in Japan, where approximately one-fifth of meals contain seaweed.^{1–3} Inclusion of seaweeds in Western diets has traditionally been limited to artisanal practices and coastal communities but has gained wider consumer interest in recent years, courtesy of the health-food industry.⁴ The recent surge of interest in seaweed is fueled by attention on the bioactive components of seaweed, which have potential applications in the lucrative functional food and nutraceutical industries, with impetus toward the alleviation of metabolic risk factors such as hyperglycemia, hypercholesterolemia, and hyperlipidemia.⁵ The candidate bioactive

components of interest to industry include isolated polysaccharides (eg, alginate, fucoidan), proteins (eg, phycobiliproteins), polyphenols (eg, phlorotannins), carotenoids (eg, fucoxanthin), and n-3 long-chain polyunsaturated fatty acids (eg, eicosapentaenoic acid). Scientific experiments and human studies to date have focused predominantly on brown seaweeds and derivatives, largely because of their commercial abundance and perceived sustainability.

Despite the nutritional attributes of red seaweeds such as *Porphyra* spp (also known as nori) and *Palmaria palmata* (dulse), which have a high protein content, relatively few investigations have focused on red seaweeds as a source of bioactive components. Current understanding of the health-promoting activities of red seaweeds derives from an abundance of in vitro studies and in vivo animal studies. There are only limited reports of green seaweeds contributing to

Affiliation: P. Cherry, C. O'Hara, P.J. Magee, E.M. McSorley, and P.J. Allsopp are with the Nutrition Innovation Centre for Food and Health, School of Biomedical Sciences, Ulster University, Coleraine, United Kingdom. C. O'Hara is with VOYA Products Limited, County Sligo, Ireland.

Correspondence: P.J. Allsopp, Nutrition Innovation Centre for Food and Health, School of Biomedical Sciences, Ulster University, Cromore Road, Coleraine, Co. Londonderry BT52 1SA, United Kingdom. Email: pj.allsopp@ulster.ac.uk.

Key words: functional foods, heavy metals, marine bioactives, nutrition, seaweed.

© The Author(s) 2019. Published by Oxford University Press on behalf of the International Life Sciences Institute.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

dietary intake of either essential nutrients or bioactive components, despite the potential for transient algal blooms to be exploited.⁶

Aquaculture is recognized as the most sustainable means of seaweed production and accounts for approximately 27.3 million tonnes (96%) of global seaweed production per annum, yet the growing demand for seaweed-based food ingredients calls for more established guidelines and regulations to ensure sustainability.⁷ Future considerations for stakeholder management include resource ownership; best practices for cultivation; harvesting rights/licensing; certification/validation of origin; overexploitation; biomass regrowth; environmental impacts; and the development of a sustainable value chain within the agrifood sector.²

An abundance of commercially available seaweed products, including both whole seaweed and seaweed extracts, are marketed both directly and indirectly as value-added products for the promotion of health in the supplement market. The health claims associated with seaweed products are often based on insufficient (or completely absent) evidence from human intervention studies to substantiate such statements. Furthermore, there are considerable safety concerns related to potential adverse events associated with seaweed consumption, particularly in light of the variable and potentially dangerously high concentrations of iodine and heavy metals (including arsenic species) in certain seaweeds.^{8,9} There is currently limited legislation to require food or supplement companies to disclose mineral, heavy metal, or iodine content of seaweed products or to provide guidance on a safe portion size of certain whole seaweeds in order to prevent excess intakes.⁴ Ultimately, if seaweeds are to contribute to future global food security, either in their whole form or via extraction of their nutrients, the industry should develop a sustainable heavy metal/iodine monitoring program or, alternatively, identify novel processing technologies to ensure that unsafe components such as arsenic are minimized to safe levels, thus protecting the food chain.^{2,10–14}

The health benefits of seaweed, beyond the provision of essential nutrients, have been supported by *in vitro* studies and some animal studies; however, many of these studies have inappropriate biomarkers to substantiate a claim and have not progressed to suitably designed human intervention trials to evaluate efficacy. The limited evidence that does exist makes some seaweed components attractive as functional food ingredients, but more human evidence (including mechanistic evidence) is needed to evaluate both the nutritional benefit conferred and the efficacy of purported bioactives and to determine any potential adverse effects. Through an evaluation of the nutritional composition of edible seaweeds, this review summarizes

the available evidence and outlines the potential risks and health benefits of consuming whole seaweeds, extracted bioactive components, and seaweed-based food products in humans. Additionally, it identifies future opportunities for functional food and nutraceutical applications.

NUTRITIONAL COMPOSITION OF EDIBLE SEAWEEDS

A number of edible seaweeds are recognized as novel foods in Europe, although the nutritional composition of brown, red, and green seaweeds varies between species, season, and ecology of the harvesting location.¹⁵ Therefore, there is a need to characterize the composition of seaweeds in relation to the influence of location and seasonality on seaweed content. Current efforts to catalog information on the variability of nutritional composition will facilitate the identification of optimal harvesting periods and/or locations for a given species. Such information would aid the functional food industry in targeting optimal conditions for isolating specific bioactive components.^{16–18} Table 1,^{17,19–32} Table 2,^{19–22,26,27,29–31,33–42} and Table 3^{19–24,26,27,29,30,36,43–53} present the macronutrient content of multiple brown, red, and green seaweeds, respectively, and consider a 5-g serving relative to reference nutrient intakes. To provide a basis for comparison, Tables S1 and S2 in the Supporting Information online present the same nutritional information for a selection of dried seaweed products commercially available throughout the United Kingdom and the Republic of Ireland.

Protein

The protein content of seaweed has gained considerable attention, given the emerging challenges to improve food security by identifying alternative and sustainable protein sources.⁵⁴ As outlined in Tables 1, 2, and 3, the protein content ranges from 5.02% to 19.66% in brown seaweeds; from 0.67% to 45.0% in red seaweeds; and from 3.42% to 29.80% in green seaweeds. A 5-g portion of dried brown, red, and green seaweed corresponds, respectively, to a maximum of 1.97%, 4.5%, and 2.98% of the Reference Nutrient Intake for protein. On a gram-for-gram basis, seaweeds have protein and amino acid contents comparable to those of beef; however, seaweeds are consumed in much smaller quantities.⁵⁵ It should also be noted that the protein content of seaweed is often derived from total nitrogen by using a conversion factor of 6.25 (Kjeldahl method), which likely produces an overestimate, given the nonprotein sources of nitrogen in seaweed. Hence, species-specific conversion factors ranging from 3.57 to 5.72 have been proposed for seaweed.⁵⁶ The amino acid composition of proteins

Table 1 Macronutrient content of brown seaweeds

Reference	Seaweed	Country	Date harvested	Protein (%)	Percent RNI supplied by 5-g portion	Lipid (%)	Percent RNI supplied by 5-g portion	Carbohydrate (%)	Percent RNI supplied by 5-g portion	Fiber (%)	Percent RNI supplied by 5-g portion
Maehre et al (2014) ¹⁹	<i>Alaria esculenta</i>	Norway	May 2010	9.11	0.91	1.40	0.10	—	—	—	—
Schiener et al (2015) ¹⁷	<i>Alaria esculenta</i>	Scotland	Mar 2011 – Jul 2011	11.04	1.10	—	—	72.10	1.39	—	—
Tabarsa et al (2012) ²⁰	<i>Colpomenia sinuosa</i>	Iran	Apr 2008	10.11	1.01	1.46	0.10	—	—	9.50	1.58
El-Said & El-Sikaily (2013) ²¹	<i>Colpomenia sinuosa</i>	Egypt	Apr 2011	—	—	—	—	11.80	0.23	—	—
Rohani-Ghadikolaei et al (2012) ²²	<i>Colpomenia sinuosa</i>	Iran	—	9.20	0.92	1.50	0.11	32.10	0.62	—	—
Tabarsa et al (2012) ²⁰	<i>Dictyota dichotoma</i>	Iran	Apr 2008	17.73	1.77	2.94	0.21	—	—	10.50	1.75
Smith et al (2010) ²³	<i>Durvillaea antarctica</i>	New Zealand	Apr 2004	7.26	0.73	2.03	0.15	58.82	1.13	—	—
Ortiz et al (2006) ²⁴	<i>Durvillaea antarctica</i>	Chile	Nov 2013	10.40	1.04	0.80	0.06	70.90	1.36	71.40	11.90
Ortiz et al (2006) ²⁴	<i>Durvillaea antarctica</i>	Chile	Nov 2013	11.60	1.16	4.30	0.31	58.40	1.12	56.40	9.40
Smith et al (2010) ²³	<i>Ecklonia radiata</i>	New Zealand	Aug 2004	9.60	0.96	1.80	0.13	66.90	1.29	—	—
Smith et al (2010) ²³	<i>Ecklonia spp</i>	New Zealand	—	9.78	0.98	0.80	0.06	69.61	1.34	—	—
Mišurcová et al (2010) ²⁵	<i>Eisenia bicyclis</i>	Japan	—	—	—	—	—	—	—	11.15	1.86
Paiva et al (2014) ²⁶	<i>Fucus spiralis</i>	Portugal	Jan 2013	9.71	0.97	5.23	0.37	17.59	0.34	—	—
Marshall et al (2007) ²⁷	<i>Fucus serratus</i>	United Kingdom	—	17.40	1.74	1.80	0.13	—	—	26.20	4.37
Maehre et al (2014) ¹⁹	<i>Fucus vesiculosus</i>	Norway	May 2010	6.11	0.61	3.08	0.22	—	—	—	—
Sanchez-Machado et al (2004) ²⁸	<i>Himanthalia elongata</i>	Spain	—	5.46	0.55	0.97	0.07	—	—	—	—
Sanchez-Machado et al (2004) ²⁸	<i>Himanthalia elongata</i>	Spain	—	10.95	1.10	0.93	0.07	—	—	—	—
Mišurcová et al (2010) ²⁵	<i>Hizikia fusiformis</i>	Japan	—	—	—	—	—	—	—	17.52	2.92
Smith et al (2010) ²³	<i>Hormosira banksii</i>	New Zealand	Apr 2004	6.07	0.61	2.63	0.19	62.90	1.21	—	—
Maehre et al (2014) ¹⁹	<i>Laminaria digitata</i>	Norway	May 2010	5.31	0.53	0.99	0.07	—	—	—	—
Schiener et al (2015) ¹⁷	<i>Laminaria digitata</i>	Scotland	Aug 2010 – Oct 2011	6.90	0.69	—	—	70.70	1.36	—	—
Marshall et al (2007) ²⁷	<i>Laminaria digitata</i>	United Kingdom	—	15.90	1.59	0.50	0.04	—	—	16.60	2.77
Maehre et al (2014) ¹⁹	<i>Laminaria hyperborea</i>	Norway	May 2010	5.02	0.50	1.28	0.09	—	—	—	—
Schiener et al (2015) ¹⁷	<i>Laminaria hyperborea</i>	Scotland	Aug 2010 – Oct 2011	6.80	0.68	—	—	65.50	1.26	—	—
Mišurcová et al (2010) ²⁵	<i>Laminaria japonica</i>	Japan	—	—	—	—	—	—	—	10.45	1.74
Sanchez-Machado et al (2004) ²⁸	<i>Laminaria ochroleuca</i>	Spain	—	7.49	0.75	0.92	0.07	—	—	—	—
Smith et al (2010) ²³	<i>Macrocystis spp</i>	New Zealand	—	11.02	1.10	1.56	0.11	44.54	0.86	—	—
Tabarsa et al (2012) ²⁰	<i>Padina pavonica</i>	Iran	Apr 2008	11.83	1.18	1.79	0.13	—	—	11.00	1.83
Maehre et al (2014) ¹⁹	<i>Pelvetia canaliculata</i>	Norway	May 2010	5.72	0.57	4.78	0.34	—	—	—	—
Schiener et al (2015) ¹⁷	<i>Saccharina latissima</i>	Scotland	Aug 2010 – Oct 2011	7.10	0.71	—	—	63.10	1.21	—	—
Sanchez-Machado et al (2004) ²⁸	<i>Saccorhiza polyschides</i>	Spain	—	13.10	1.31	0.70	0.05	—	—	—	—
Rodrigues et al (2015) ²⁹	<i>Saccorhiza polyschides</i>	Portugal	Apr 2012	14.44	1.44	1.10	0.08	45.60	0.88	—	—
Rohani-Ghadikolaei et al (2012) ²²	<i>Sargassum ilicifolium</i>	Iran	—	8.90	0.89	2.00	0.14	32.90	0.63	—	—
Matanjun et al (2009) ³⁰	<i>Sargassum polycystum</i>	Borneo	—	5.40	0.54	0.29	0.02	33.49	0.64	39.67	6.61
Marinho-Soriano et al (2006) ³¹	<i>Sargassum vulgare</i>	Brazil	Jul 2000 – Jun 2001	13.61	1.36	0.49	0.04	61.60	1.18	7.74	1.29
El-Said & El-Sikaily (2013) ²¹	<i>Sargassum linifolium</i>	Egypt	Apr 2011	—	—	—	—	8.59	0.17	—	—
Rodrigues et al (2015) ²⁹	<i>Sargassum muticum</i>	Portugal	Apr 2012	16.90	1.69	1.45	0.10	49.30	0.95	—	—
Peng et al (2013) ³²	<i>Sargassum naohouense</i>	China	Jul 2011	11.20	1.12	1.06	0.08	47.43	0.91	4.83	0.81
Smith et al (2010) ²³	<i>Undaria pinnatifida</i>	New Zealand	—	14.21	1.42	3.13	0.22	45.08	0.87	—	—
Sanchez-Machado et al (2004) ²⁸	<i>Undaria pinnatifida</i>	Spain	—	18.00	1.80	1.05	0.08	—	—	—	—
Smith et al (2010) ²³	<i>Undaria pinnatifida</i>	New Zealand	Apr – Sep 2004	19.66	1.97	3.30	0.24	50.40	0.97	—	—
Mišurcová et al (2010) ²⁵	<i>Undaria pinnatifida</i>	Japan	—	—	—	—	—	—	—	9.03	1.51
Mišurcová et al (2010) ²⁵	<i>Undaria pinnatifida</i>	Japan	—	—	—	—	—	—	—	15.53	2.59

Abbreviation: RNI, Reference Nutrient Intake.

310

(continued)

Table 2 Continued

Reference	Seaweed	Country	Date harvested	Protein (%)	Percent RNI supplied by 5-g portion	Lipid (%)	Percent RNI supplied by 5-g portion	Carbohydrate (%)	Percent RNI supplied by 5-g portion	Fiber (%)	Percent RNI supplied by 5-g portion
Rodrigues et al (2015) ²⁹	<i>Osmundea pinnatifida</i>	Portugal	Apr 2012	23.80	2.38	0.90	0.06	32.40	0.62	—	—
Marshall et al (2007) ²⁷	<i>Osmundea pinnatifida</i>	United Kingdom	—	27.30	2.73	4.30	0.31	—	—	25.60	4.27
Maehre et al (2014) ¹⁹	<i>Palmaria palmata</i>	Norway	Jun 2012	12.26	1.23	1.36	0.10	—	—	—	—
Pajkola et al (2016) ³³	<i>Palmaria palmata</i>	Denmark	Sep 2011	14.90	1.49	1.20	0.09	71.00	1.37	—	—
Misurcová et al (2010) ²⁵	<i>Palmaria palmata</i>	United States	—	—	—	—	—	—	—	5.05	0.84
Sanchez-Machado et al (2004) ²⁸	<i>Palmaria</i> spp	Spain	—	13.87	1.39	1.80	0.13	—	—	—	—
Pajkola et al (2016) ³³	<i>Phycodrys rubens</i>	Denmark	Sep 2011	28.80	2.88	1.30	0.09	40.20	0.77	—	—
Gressler et al (2011) ⁴⁰	<i>Plocamium brasiliense</i>	Brazil	—	15.72	1.57	3.63	0.26	52.03	1.00	—	—
Marshall et al (2007) ²⁷	<i>Polysiphonia</i> spp	United Kingdom	—	31.80	3.18	0.05	0.00	—	—	52.80	8.80
Cian et al (2014) ⁴¹	<i>Porphyra columbina</i>	Argentina	Aug – Oct 2010	24.61	2.46	0.25	0.02	—	—	48.02	8.00
Sanchez-Machado et al (2004) ²⁸	<i>Porphyra</i> spp	Spain	—	24.11	2.41	1.03	0.07	—	—	—	—
Paiva et al (2014) ²⁶	<i>Porphyra</i> spp	Portugal	Jan 2007	24.82	2.48	8.88	0.63	25.37	0.49	—	—
Smith et al (2010) ²³	<i>Porphyra</i> spp	New Zealand	—	26.36	2.64	3.03	0.22	43.99	0.85	—	—
Smith et al (2010) ²³	<i>Porphyra</i> spp	New Zealand	May – Oct 2004	32.71	3.27	2.00	0.14	45.40	0.87	—	—
Marshall et al (2007) ²⁷	<i>Porphyra</i> spp	United Kingdom	—	44.00	4.40	0.70	0.05	—	—	33.50	5.58
Cofrades et al (2010) ⁴²	<i>Porphyra umbilicalis</i>	Spain	—	39.00	3.90	—	—	—	—	—	—
El-Said & El-Sikaily (2013) ²¹	<i>Pterocladia capillacea</i>	Egypt	Apr 2011	—	—	—	—	9.64	0.19	—	—
El-Said & El-Sikaily (2013) ²¹	<i>Pterocladia capillacea</i>	Egypt	Apr 2011	—	—	—	—	11.20	0.22	—	—
El-Said & El-Sikaily (2013) ²¹	<i>Pterocladia capillacea</i>	Egypt	Apr 2011	—	—	—	—	7.89	0.15	—	—
El-Said & El-Sikaily (2013) ²¹	<i>Pterocladia capillacea</i>	Egypt	Apr 2011	—	—	—	—	8.06	0.16	—	—
Paiva et al (2014) ²⁶	<i>Pterocladia capillacea</i>	Azores (Portugal)	Jan 2013	—	—	4.32	0.31	—	—	—	—
Maehre et al (2014) ¹⁹	<i>Vertebrata lanosa</i>	Norway	June 2012	11.56	1.16	1.55	0.11	—	—	—	—

Abbreviation: RNI, Reference Nutrient Intake.

Table 3 Macronutrient content of green seaweeds

Reference	Seaweed	Country	Date harvested	Protein (%)	Percent RNI supplied by 5-g portion	Lipid (%)	Percent RNI supplied by 5-g portion	Carbohydrate (%)	Percent RNI supplied by 5-g portion	Fiber (%)	Percent RNI supplied by 5-g portion
Nguyen et al (2011) ⁴³	<i>Caulerpa lentillifera</i>	Taiwan	–	9.26	0.93	1.57	0.11	64.00	1.23	2.97	0.50
Matanijun et al (2009) ³⁰	<i>Caulerpa lentillifera</i>	Borneo	–	10.41	1.04	1.11	0.08	38.66	0.74	32.99	5.50
Ratana-Arporn & Chirapart (2006) ⁴⁴	<i>Caulerpa lentillifera</i>	Thailand	March	12.49	1.25	0.86	0.06	59.27	1.14	3.17	0.53
Mandlik et al (2014) ⁴⁵	<i>Caulerpa racemosa</i>	India	–	–	–	–	–	10.02	0.19	–	–
Kokilam & Vasuki (2013) ⁴⁶	<i>Caulerpa taxifolia</i>	India	–	12.44	1.24	0.32	0.02	23.86	0.46	–	–
Maehre et al (2014) ¹⁹	<i>Cladophora rupestris</i>	Norway	May 2010	3.42	0.34	0.76	0.05	–	–	–	–
Marsham et al (2007) ²⁷	<i>Cladophora rupestris</i>	United Kingdom	–	29.80	2.98	1.00	0.07	–	–	45.70	7.62
Rodrigues et al (2015) ²⁹	<i>Codium tomentosum</i>	Portugal	April 2012	18.80	1.88	3.60	0.26	32.80	0.63	–	–
El-Said & El-Sikaily (2013) ²¹	<i>Codium tomentosum</i>	Egypt	April 2011	–	–	–	–	11.15	0.21	–	–
Aguilera-Morales et al (2005) ⁴⁷	<i>Enteromorpha</i> spp	Mexico	Winter 1997	9.45	0.95	2.24	0.16	–	–	–	–
Aguilera-Morales et al (2005) ⁴⁷	<i>Enteromorpha</i> spp	Mexico	Winter 1998	14.10	1.41	2.27	0.16	–	–	–	–
Pirian et al (2016) ⁴⁸	<i>Ulva californica</i>	Iran	March 2015	15.20	1.52	3.75	0.27	–	–	–	–
Pirian et al (2016) ⁴⁸	<i>Ulva californica</i>	Iran	February 2015	15.76	1.58	3.45	0.25	–	–	–	–
Pirian et al (2016) ⁴⁸	<i>Ulva compressa</i>	Iran	February 2015	18.12	1.81	1.03	0.07	–	–	–	–
Pirian et al (2016) ⁴⁸	<i>Ulva compressa</i>	Iran	March 2015	18.64	1.86	0.90	0.06	–	–	–	–
Paiva et al (2016) ⁴⁹	<i>Ulva compressa</i>	Azores (Portugal)	April 2013	–	–	1.67	0.12	–	–	–	–
Pirian et al (2016) ⁴⁸	<i>Ulva fasciata</i>	Iran	March 2015	14.06	1.41	0.56	0.04	–	–	–	–
Pirian et al (2016) ⁴⁸	<i>Ulva fasciata</i>	Iran	February 2015	14.69	1.47	0.47	0.03	–	–	–	–
Pirian et al (2016) ⁴⁸	<i>Ulva flexuosa</i>	Iran	March 2015	10.55	1.06	2.82	0.20	–	–	–	–
Pirian et al (2016) ⁴⁸	<i>Ulva flexuosa</i>	Iran	March 2015	11.23	1.12	2.34	0.17	–	–	–	–
Escobido et al (2016) ⁵⁰	<i>Ulva intestinalis</i>	Philippines	January – April 2016	5.57	0.56	0.43	0.03	37.28	0.72	–	–
Rohani-Ghadikolaei et al (2012) ²²	<i>Ulva intestinalis</i>	Iran	–	10.50	1.05	2.90	0.21	35.50	0.68	–	–
Maehre et al (2014) ¹⁹	<i>Ulva intestinalis</i>	Norway	May 2010	11.33	1.13	1.62	0.12	–	–	–	–
El-Said & El-Sikaily (2013) ²¹	<i>Ulva intestinalis</i>	Egypt	April 2011	–	–	–	–	8.72	0.17	–	–
Wong & Cheung (2000) ³⁶	<i>Ulva lactuca</i>	Hong Kong	December 1997	7.06	0.71	1.64	0.12	–	–	55.40	9.23
Yaich et al (2011) ⁵¹	<i>Ulva lactuca</i>	Tunisia	July 2007	8.46	0.85	7.87	0.56	–	–	54.90	9.15
Maehre et al (2014) ¹⁹	<i>Ulva lactuca</i>	Norway	June 2012	8.65	0.87	2.00	0.14	–	–	–	–
Tabarsa et al (2012) ²⁰	<i>Ulva lactuca</i>	Iran	April 2008	10.69	1.07	0.99	0.07	–	–	5.60	0.93
Pirian et al (2016) ⁴⁸	<i>Ulva lactuca</i>	Iran	February 2015	20.85	2.09	0.85	0.06	–	–	–	–
Pirian et al (2016) ⁴⁸	<i>Ulva lactuca</i>	Iran	March 2015	21.55	2.16	0.75	0.05	–	–	–	–
Bikker et al (2016) ⁵²	<i>Ulva lactuca</i>	Ireland	May 2015	26.30	2.63	2.11	0.15	24.00	0.46	–	–
Ortiz et al (2006) ²⁴	<i>Ulva lactuca</i>	Chile	November 2013	27.20	2.72	0.30	0.02	61.50	1.18	60.50	10.08
Marsham et al (2007) ²⁷	<i>Ulva lactuca</i>	United Kingdom	–	29.00	2.90	0.50	0.04	–	–	32.90	5.48
El-Said & El-Sikaily (2013) ²¹	<i>Ulva lactuca</i>	Egypt	April 2011	–	–	–	–	11.15	0.21	–	–
El-Said & El-Sikaily (2013) ²¹	<i>Ulva lactuca</i>	Egypt	April 2011	–	–	–	–	10.95	0.21	–	–
El-Said & El-Sikaily (2013) ²¹	<i>Ulva lactuca</i>	Egypt	April 2011	–	–	–	–	11.54	0.22	–	–
El-Said & El-Sikaily (2013) ²¹	<i>Ulva lactuca</i>	Egypt	April 2011	–	–	–	–	11.28	0.22	–	–

(continued)

Table 3 Continued

Reference	Seaweed	Country	Date harvested	Protein (%)	Percent RNI supplied by 5-g portion	Lipid (%)	Percent RNI supplied by 5-g portion	Carbohydrate (%)	Percent RNI supplied by 5-g portion	Fiber (%)	Percent RNI supplied by 5-g portion
El-Said & El-Sikaily (2013) ²¹	<i>Ulva lactuca</i>	Egypt	April 2011	—	—	—	—	11.41	0.22	—	—
El-Said & El-Sikaily (2013) ²¹	<i>Ulva lactuca</i>	Egypt	April 2011	—	—	—	—	11.15	0.21	—	—
El-Said & El-Sikaily (2013) ²¹	<i>Ulva lactuca</i>	Egypt	April 2011	—	—	—	—	10.16	0.20	—	—
Rohani-Ghadikolaei et al (2012) ²²	<i>Ulva lactuca</i>	Iran	—	17.10	1.71	3.60	0.26	59.10	1.14	—	—
Pirian et al (2016) ⁴⁸	<i>Ulva linza</i>	Iran	March 2015	10.16	1.02	3.70	0.26	—	—	—	—
Pirian et al (2016) ⁴⁸	<i>Ulva linza</i>	Iran	March 2015	10.45	1.05	3.30	0.24	—	—	—	—
Pirian et al (2016) ⁴⁸	<i>Ulva prolifera</i>	Iran	February 2015	19.87	1.99	6.06	0.43	—	—	—	—
Pirian et al (2016) ⁴⁸	<i>Ulva prolifera</i>	Iran	March 2015	20.30	2.03	6.06	0.43	—	—	—	—
Ratana-Arporn & Chirapart (2006) ⁴⁴	<i>Ulva reticulata</i>	Thailand	May	21.06	2.11	0.75	0.05	55.77	1.07	4.84	0.81
Taboada et al (2010) ⁵³	<i>Ulva rigida</i>	Spain	—	17.80	1.78	0.90	0.06	42.60	0.82	11.90	1.98
Paiva et al (2014) ²⁶	<i>Ulva rigida</i>	Azores (Portugal)	April 2013	—	—	1.02	0.07	—	—	—	—
Smith et al (2010) ²³	<i>Ulva stenophylla</i>	New Zealand	April 2004	20.43	2.04	1.24	0.09	55.60	1.07	—	—

Abbreviation: RNI, Reference Nutrient Intake.

is critical to determining the value of proteins to the human diet, particularly in achieving an adequate intake of essential amino acids. However, the digestibility of seaweed protein within the gastrointestinal tract will significantly affect the nutritional value of the protein, with protein-polysaccharide interactions reducing digestion efficiency considerably.

An overview of the amino acid contents of several brown, red, and green seaweeds is presented in Tables S3, S4, and S5 in the Supporting Information online. Seaweeds are a source of lysine,^{58,59} an essential amino acid often present in limited quantities in terrestrial plant protein sources such as corn, maize, soy, rice, and wheat.⁵⁷ An 8-g portion of *Palmaria palmata* contains up to 21.9% of the recommended daily intake of cysteine, yet the total protein content of *Palmaria palmata* varies seasonally.⁵⁸ For example, protein content was reported as 21.9% in winter/spring and as 11.9% in summer/autumn, with essential amino acids constituting 26% to 50% of the protein.⁶⁰ Thus, exploiting seaweeds as nonanimal protein sources may be possible through harvesting plans that optimize protein and amino acid contents.

The digestibility of protein in species of edible seaweeds, estimated by in vitro methods, is reported as follows: *Fucus vesiculosus*, 14.7%; *Laminaria digitata*, 16.9%; *Undaria pinnatifida*, 28.0%; *Chondrus crispus*, 45.0%; *Porphyra tenera*, 69.4%⁶¹; *Palmaria palmata*, 56.0%⁶⁰; and *Porphyra columbina*, 74.3%.⁴¹ The digestibility of protein from *Undaria pinnatifida* and *Porphyra tenera* in rodents is reported as 86.1% and 86.2%, respectively, while the digestibility of *Undaria pinnatifida* protein in humans is reported as 70.0%, which is similar to the digestibility of protein from terrestrial plants.^{62,63} Although data on in vivo digestibility suggest that seaweed protein is bioaccessible, protein-polysaccharide interactions within the seaweed matrix could prevent the formation of enzyme-substrate complexes and hinder proteolysis of seaweed proteins. Indeed, enzymatic treatment with xylanase and cellulase polysaccharidases improved *Palmaria palmata* protein bioaccessibility 1.7-fold and 3-fold, respectively.⁶⁵ This may favor the use of seaweed protein extracts to provide the maximal protein and amino acid content, with possible food, feed, supplement, and nutraceutical applications.^{63,64} Methods for extracting protein from brown, red, and green seaweeds are described comprehensively elsewhere; for example, the use of proteolytic and saccharolytic enzymes such as Celluclast or Shearzyme are reported to improve both protein extraction yield and endogenous digestion.^{66–69}

Up to now, the bioactivities reported in the literature pertained to peptides extracted from red seaweeds such as *Palmaria palmata* and *Porphyra* spp and from

brown seaweeds such as *Undaria pinnatifida* and were associated with antihypertensive, antioxidant, and anti-diabetic effects.⁷⁰ Among the effects reported are cardioprotective effects such as reduced blood pressure via inhibition of angiotensin-converting enzyme,^{71–74} anti-diabetic activity via inhibition of dipeptidyl-peptidase 4,⁷⁷ and promotion of iron absorption.⁷⁶ The potential application of seaweed peptides, which have antioxidant properties,⁷⁵ as food preservatives has also been suggested.⁷² Therefore, protein extracts from seaweeds hold promise as a protein source, providing their bioactivity is validated in humans.

It is estimated that 56 million metric tonnes of algae will be required per annum as an alternative protein source by 2054, which will represent 5.94% of global protein demand.⁷⁸ Given the variability of both the content and the bioavailability of protein from whole seaweeds, protein extracts may contribute substantially to nonanimal protein sources in the future.

Dietary fiber

Many populations are failing to meet daily requirements for dietary fiber intake.^{79,80} The potential functional properties of dietary fiber are associated with the viscous and water-binding properties of fiber within the gastrointestinal tract.⁸² As a result, fiber has been suggested to promote satiety and weight loss; delay gastric emptying to improve glycemic control; enhance stool bulking to reduce gut transit time and increase defecation frequency; and enhance bile acid excretion, resulting in reduced low-density lipoprotein cholesterol (LDL-C) in blood.^{81–83} Dietary fiber components are also suggested to improve health via their fermentation by the colonic microbiota, which can favorably alter gut microbial composition and enhance the production of health-associated volatile fatty acids such as acetate, propionate, and butyrate. The fiber-induced alterations to the microbiota composition and the associated metabolites produced are increasingly associated with the promotion of gastrointestinal, cardiometabolic, immune, bone, and mental health.⁸⁴

Owing to the range of proposed beneficial health effects associated with consumption of dietary fiber, there is increasing interest from the food industry in identifying sustainable, alternative sources of dietary fiber.^{81,83} Seaweed, with its high fiber content, is a promising candidate. However, the contribution of whole seaweed to the currently recommended intake of dietary fiber, ie, 25 g/d, is limited, with a 5-g serving of brown, red, or green seaweed contributing up to 14.28%, 10.64%, or 12.10% of dietary fiber intake, respectively (Tables 1, 2, and 3).⁷⁹ This has led to increasing interest in the industrially applicable extraction and

isolation of individual fiber components from seaweed. Seaweeds contain a diverse range of fiber components. Brown seaweeds contain alginate,⁸⁵ laminarin,⁸⁶ and fucoidan polysaccharides⁸⁹; red seaweeds contain agar, carrageenan, porphyran, and xylan^{88,90}; and green seaweeds contain ulvan, xylan, and cellulose.⁸⁷

While some seaweed-derived fibers (alginate, carrageenan, and agar) have been used for decades for their emulsifying, stabilizing, and thickening characteristics to improve the sensory properties of food, there is limited interest in their application as functional dietary fibers. The existing widespread use of these seaweed-derived fibers in the food industry ensures they are safe for human consumption, according to the European Food Safety Authority (EFSA) and the US Food and Drug Administration. Thus, alginate isolated from brown seaweeds, long used by the food industry, is a leading candidate for application in the functional food market.^{91–93} Fucoidan was recently classified by the EFSA as a novel food,⁹⁴ making it another candidate for an emerging functional food ingredient, while suggestions that low-molecular-weight carrageenan components (< 50 kDa) may negatively impact health (on the basis of proinflammatory properties) have tempered interest in the potential use of carrageenan as a functional ingredient.⁹⁵ Other seaweed fibers, such as xylan, laminarin, and ulvan, have not received official EFSA approval, and thus more research is needed to ascertain whether these carbohydrates are safe for human consumption. Once these seaweed-derived fiber components have been deemed safe, they will likely be marketed as nutritional ingredients, provided the associated health claims are substantiated.

The majority of research on the health benefits of seaweed-derived dietary fiber components in humans has focused on potential antiobesogenic effects, including improved satiation, delayed nutrient absorption, and delayed gastric emptying, but the effects of whole seaweeds containing alginate appear to be limited.^{85,96,97} Several placebo-controlled intervention trials in humans have shown alginate consumption to significantly impact appetite and food intake. An acute study by Peters et al⁹⁸ showed that an alginate drink enhanced self-reported satiety and reduced the feeling of hunger in a dose-dependent manner when compared with placebo. Another parallel study in overweight men showed that consumption of an *Ascophyllum nodosum*-enriched (4%) bread reduced energy intake by 109 kcal and 506 kcal at 4 hours and 24 hours post consumption, respectively, compared with an isocaloric placebo.⁹⁹ Similar results were reported when consumption of a preload alginate drink reduced energy intake by 44 kcal following an ad libitum lunch.¹⁰⁰ A crossover study reported that daily energy intake was reduced by

135 kcal when participants consumed alginate (1.5 g/100 mL) prior to meals,¹⁰¹ but no significant effect of a preload alginate drink on measures of energy intake or concentration of satiety hormones in overweight/obese individuals was reported elsewhere.¹⁰² Alginate appears to affect appetite and food intake, yet research is needed to characterize the action of alginates by examining both the relationship between structure and function (particularly molecular weight and the ratio of guluronate to mannuronate) and the role of the gelling capacity of alginate. Research into the mechanism of action of alginate is required, given that alginate does not seem to affect gastric emptying.^{100,102} The formulation of alginate food products organoleptically acceptable to the consumer is another consideration for industry. Longer-term studies are required to demonstrate the effects of alginate on appetite control and weight management.

There is also considerable interest in the effect of alginate on glycemic control, particularly its impact on postprandial glucose absorption. A review of the evidence by the EFSA concluded that sodium alginate failed to reduce postprandial glycemic responses without a disproportionate increase in postprandial insulinemic responses, and thus a health claim was rejected.^{83,103} Other fibers, such as beta glucan, have received favorable EFSA opinions for their ability to reduce postprandial glucose absorption by slowing the rate of gastric emptying.⁸³ The effect of alginate on glucose metabolism, particularly the postprandial insulinemic response, needs to be further investigated.

The recent designation of fucoidan as Generally Recognized as Safe (GRAS) by the US Food and Drug Administration¹⁰⁴ and as a novel food by the European Union,⁹⁴ along with accumulating in vitro and in vivo evidence of fucoidan's potential antiobesogenic effects,¹⁰⁵ make fucoidan an attractive ingredient for the functional food industry.¹⁰⁶ Nevertheless, only 1 human study has investigated the antiobesogenic effects of seaweed-derived fucoidan. A randomized, double-blind, parallel, placebo-controlled trial in an overweight/obese cohort showed that participants who consumed fucoidan (500 mg/d) for 3 months had significantly reduced diastolic blood pressure and LDL-C compared with those who received placebo.¹⁰⁷ No changes in weight, waist circumference, body mass index (BMI), adiposity, systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol (HDL-C), blood glucose, or blood triglycerides were observed; however, blood insulin and homeostasis model assessment of insulin resistance (HOMA-IR) were increased in the fucoidan group compared with baseline values, but not compared with the placebo group. The authors suggested that fucoidan consumption downregulated

expression of the transcription factor peroxisome proliferator-activated receptor- γ (PPAR γ) to suppress adipocyte differentiation and insulin signaling.

Conversely, evidence from animal models of obesity and diabetes suggests that low-molecular-weight fucoidan could ameliorate dyslipidemia and improve insulin sensitivity through the activation of insulin signaling pathways in adipocytes and hepatocytes.^{105,108–111} Further evidence from human intervention trials is required to understand how dietary fucoidan may modulate host glucose and lipid metabolism to exert antiobesogenic and antidiabetic effects. This may also require an understanding of how the molecular weight of fucoidan affects bioactivity.

Fucoidan is also reported to have anticoagulant properties, serving as a catalyst for antithrombin-mediated and heparin cofactor II-mediated inhibition of thrombin.^{112–114} Oral administration of *Undaria pinnatifida* extract (9 g/d) with 75% fucoidan (molecular weight \approx 713 kDa) for 12 days increased activated partial thromboplastin time, decreased thrombin time, and increased antithrombin-III compared with placebo, although the authors concluded the improvements were small and the impact of oral delivery may be limited.¹¹² Another study investigated oral administration of fucoidan (extracted from *Laminaria japonica*, molecular weight \approx 300 kDa) at a dosage of 400 mg/d for 5 weeks and reported a significant reduction in thrombus lysis time, although a fucoidan-specific monoclonal antibody enzyme-linked immunosorbent assay failed to detect fucoidan in the blood of study participants.¹¹⁵ This suggests fucoidan may not be bioavailable in humans, although in vitro and in vivo experiments have demonstrated fucoidan to be absorbed through the small intestine.¹¹⁶ The anticoagulant properties of fucoidan are gaining the attention of the pharmaceutical industry, but the use of fucoidan as a food ingredient will require much more human evidence to verify safe and efficacious doses, particularly in individuals receiving anticoagulant therapy.

There is also a wealth of evidence to support an anticancer function of fucoidan, but the majority of evidence is from in vitro or animal studies and is reviewed elsewhere.¹¹⁷ A recent clinical trial in colon cancer patients investigated the effect of an oral fucoidan supplement (4 g twice daily) administered in conjunction with chemotherapy.¹¹⁸ Patients who received fucoidan had a significantly better disease control rate compared with placebo control patients but showed no change in overall response rate, progression-free survival, overall survival, adverse effects, or quality of life. While the effect on disease control rate is a notable benefit, the role of fucoidan in cancer treatment remains unknown. Advertisement of cancer treatments is prohibited in the

United Kingdom,¹¹⁹ although legislation regarding advertisement of cancer prevention is less clear.¹²⁰ Furthermore, marketing fucoidan as a food ingredient with cancer-preventive effects is extremely difficult to substantiate and may prove very difficult within the existing regulatory environment.

There is increasing interest in the potential prebiotic effect of seaweed-derived fiber, which can modulate the composition and metabolism of the colonic microbiota, as well as growing interest in the effect of fiber fermentation on human health. Several in vitro fecal batch culture studies have demonstrated the fermentability of seaweed fiber components, noting increased production of short-chain fatty acids and modulation of gut microbial communities.^{121–125} Modulation of the gut microbiota and production of short-chain fatty acids have been observed in animal studies employing a seaweed fiber-containing diet.^{86,126} However, thus far, the only health benefit associated with the prebiotic effects of seaweed fibers is the slowing of weight gain in animals on a high-fat diet.¹²⁷ There is a lack of human intervention trials investigating the fermentability of seaweed fiber components and their potential to affect health outcomes.⁸⁴

Fat

The fat content of seaweed tends to be low relative to total dry weight. Percent fat content is highest in winter and lowest in summer, and fatty acid composition varies by season.^{16,40,128} For example, both the lipid concentration and the polyunsaturated fatty acid (PUFA) content of *Saccharina latissima* grown in integrated multitrophic aquaculture were highest in March and November, yet lowest in January.¹²⁹ Moreover, seaweed-derived lipids are highly digestible. For example, up to 98% of the fat content of *Undaria pinnatifida* (1.5% dry weight) is digestible in adults.¹²⁸

Tables 1, 2, and 3 present the total fat content of several brown, red, and green seaweeds, respectively, while Tables S6, S7, and S8 in the Supporting Information online present a breakdown of the lipid content. Total lipid content ranges from 0.29% in *Sargassum polycystum*³⁰ to 8.88% in *Porphyra* spp.²⁶ *Porphyra* spp have the lowest saturated fatty acid (SFA) content (17.4% of total fatty acids), whereas *Plocamium brasiliense* has the highest (74% of total fatty acids).⁴⁰ Monounsaturated fatty acid content relative to total fatty acid content ranged from 3.3% in *Ochtodes secundiramea* to 47.1% in *Fucus vesiculosus*.¹⁹ The PUFA content of total fatty acids ranges from 6.7% in *Ulva lactuca*⁵¹ to 69.1% in *Undaria pinnatifida*.²⁸ *Undaria pinnatifida* also has the highest PUFA:SFA ratio (3.39). As shown in Table S7 in the Supporting Information

online, *Palmaria* spp had the lowest ratio of n-6 to n-3 fatty acids,^{19,28} whereas *Gracilaria gracilis* had the highest.³⁵

Dietary reference values have not been established for PUFAs collectively, but an intake of 4% of total energy is recommended for n-6 linoleic acid.¹³⁰ Foods with a greater ratio of PUFAs to SFAs may be favorable for maintaining blood LDL-C within normal concentrations,⁸³ although more human intervention studies are needed to confirm the efficacy of PUFAs in managing dyslipidemia and attenuating low-grade inflammation.¹³¹

Evidence of bioactivity specific to seaweed lipids is limited, although male KK-Ay mice treated with 1% *Undaria pinnatifida* lipid showed a significant reduction in body weight after 4 weeks when compared with controls, while total weight of white adipose tissue was reduced in mice who consumed both the *Undaria pinnatifida* lipid and n-3 PUFA-rich scallop phospholipids.¹³² Other anti-inflammatory activities of seaweed lipids include the inhibition of lipopolysaccharide-induced inflammation in human THP-1 macrophages by lipids derived from the red seaweeds *Porphyra dioica*, *Palmaria palmata*, and *Chondrus crispus*.¹³³ Lipids extracted from *Gracilaria* spp also inhibited lipopolysaccharide-induced nitric oxide production in murine RAW 264.7 macrophage cells and decreased the viability of human T-47D breast cancer cells and of 5637 human bladder cancer cells.¹³⁴ Lastly, a C18 fatty acid extracted from *Ulva lactuca* was reported to exert an anticancer effect via activation of the Nrf2-ARE pathway to promote scavenging of reactive oxygen species.¹³⁵

Given that consumption of whole seaweed, which has a low lipid content, is unlikely to contribute significantly to dietary fat intake, macroalgae may offer a sustainable source of extractable PUFAs that can be further investigated for their anti-inflammatory effects on obesity and obesity-associated comorbidities. These extractable PUFAs may have prospective applications as dietary supplements or nutraceutical products.

Polyphenols

Polyphenols are highly complex, structural components of the cell wall. They are often bound to cell wall polysaccharides, protecting against oxidative damage.¹³⁶ Brown seaweeds contain diverse flavonoid and phlorotannin polyphenols that vary in structure, molecular weight, and level of isomerization.^{137,138}

The purported bioactivities of seaweed polyphenols include potential anticancer¹⁴¹ and antioxidant activities.^{140,142,143} Inhibition of digestive enzymes, which

may prevent lipid absorption and help maintain glucose homeostasis, has also been suggested.^{138,139}

The bioavailability of polyphenolic compounds in food varies greatly but is known to be low.¹⁴⁴ Information about the bioavailability of seaweed-derived polyphenolic compounds is limited, but a recent human intervention trial that investigated the bioavailability of polyphenols extracted from *Ascophyllum nodosum* provided initial indications of interpersonal variation in polyphenol uptake. Polyphenols detected in serum ranged from 0.011 to 7.757 $\mu\text{g/mL}$, while the total concentration of urinary phlorotannin and its metabolites ranged from 0.15 to 33.52 $\mu\text{g/mL}$.¹⁴⁵ The authors concluded, on basis of the absorption rate (6–24 hours), that the gut microbiota-mediated metabolism of the polyphenols could be a major contributor to the apparent interpersonal variation in polyphenol absorption. Consequently, more human studies are needed to investigate the bioavailability of polyphenols from ingested whole seaweeds, as there is potential for seaweed-derived fermentable fibers and polyphenols to exert synergistic effects on the gut microbiota and the host. Additional fundamental research to determine the extent to which the gut microbiota's metabolism of phlorotannins impacts the reported health benefits is also warranted.

There is considerable evidence from animal studies to support a role for an effect of seaweed polyphenols on glucose and lipid digestion and metabolism, giving rise to suggestions that these polyphenols may have potential in preventing diabetes and obesity-associated complications. Diabetic rats fed an ethanol extract (150 and 300 mg/kg) or a water extract (300 mg/kg) from *Sargassum polycystum* showed significant reductions in blood glucose, glycated hemoglobin, total cholesterol, blood triglycerides, and plasma atherogenic index.^{146,147} Polyphenols from both *Ecklonia stolonifera*¹⁴⁹ and *Ascophyllum nodosum*¹⁴⁸ have been shown to favorably alter glucose and insulin metabolism in diabetic mouse models, while *Ecklonia cava* polyphenols significantly reduced serum and liver triglycerides and total cholesterol in a diabetic mouse model.¹⁵⁰ Another study showed that a *Gelidium amansii* phenolic-rich extract reduced blood glucose and serum insulin and protected against the adverse effects of diet-induced obesity in mice via decreased blood triglycerides and total cholesterol.¹⁵¹ The mechanism of action is unknown, but current evidence supports a role in the inhibition of digestive enzymes, including α -amylase, α -glucosidase, and lipase.^{97,148,152,153}

There is limited evidence that seaweed polyphenols may exert antiobesogenic effects or may play a role in maintaining glucose homeostasis in healthy humans. For example, consumption of 500 mg of seaweed extract

containing at least 10% polyphenols did not improve the postprandial glucose concentration after a 50-g carbohydrate load (bread) compared with placebo, but it did lower the plasma insulin incremental area under the curve in healthy adults ($n = 23$).¹⁵⁴ Elsewhere, neither a 500-mg nor a 2000-mg dose of *Fucus vesiculosus* polyphenol-rich extract reduced postprandial glucose or insulin responses beyond that of the cellulose placebo after a 50-g carbohydrate load (white bread) in healthy adults ($n = 38$).¹⁵⁵

In Korean adults with increased cholesterol, however, a significant reduction in total cholesterol, LDL-C, and C-reactive protein was observed compared with baseline values following treatment with *Ecklonia cava* polyphenol extract at a dosage of 400 mg/d for 12 weeks.¹⁵⁶ Potential mechanisms of action may be associated with the inhibition of adipogenesis, as the phlorotannin dieckol has been shown to downregulate AMP-activated protein kinase (AMPK) signaling in 3T3-L1 preadipocytes.¹⁵⁷

A recent meta-analysis concluded that polyphenol-rich marine extracts could reduce fasting blood glucose, total cholesterol, and LDL-C in humans, but the few interventions conducted in humans have reported inconsistent findings for the effect of seaweed polyphenols on other biomarkers associated with risk of type 2 diabetes and cardiovascular disease, including postprandial blood glucose, fasting insulin, HDL-C, and triglycerides.¹⁵⁸

With *Ecklonia cava* phlorotannins deemed safe for use as food supplements in the European Union,¹⁵⁹ further evidence in healthy and at-risk human populations is required to ascertain the bioactivities of seaweed polyphenols.¹⁵⁵ Efforts to optimize polyphenol extraction procedures will be crucial for maximizing the potential of seaweed polyphenols as food ingredients.^{160–162}

Fucoxanthin

Carotenoids are a group of tetrapenoid compounds in seaweeds that contribute to photosynthesis. Their antioxidant properties facilitate protection from UV damage. In seaweeds, the main carotenoid with potential application in the food industry is fucoxanthin, extracted from brown seaweeds.^{163,164} Evidence suggests that fucoxanthin, through its antioxidant activity, may have potential as a food preservative to prevent lipid peroxidation in meat.¹⁶⁵

Previous research on fucoxanthin has focused on its potential as a functional food ingredient to reduce the risk of diabetes and obesity, although the evidence is derived predominantly from in vitro and animal studies. Fucoxanthin is thought to exert its effects by inhibiting the digestive enzymes α -amylase and

α -glucosidase, which in turn affects lipid metabolism by modulating leptin and adiponectin, resulting in down-regulation of lipogenesis and upregulation lipolysis.^{166,167} In several in vivo animal studies, fucoxanthin supplementation was shown to reduce blood glucose, plasma insulin, body weight gain, and accumulation of lipid in the liver; to decrease insulin resistance; and to improve the plasma lipid profile.^{168,169} Results of studies investigating the impact of fucoxanthin on cholesterol metabolism in mice have differed. Beppu et al¹⁷⁰ reported increased serum HDL-C, non-HDL-C, and total cholesterol, while Jeon et al¹⁰⁸ reported decreased serum cholesterol and increased fecal cholesterol following fucoxanthin diets.

The antiobesogenic effects of fucoxanthin have been reported in a human intervention trial in which consumption of fucoxanthin over 4 weeks significantly decreased BMI, body weight, and visceral fat area in mildly obese adults (BMI, 25–30 kg/m²), with no adverse events reported.¹⁷¹ However, mixed tocopherol and kelp extract components (the composition of which was undefined) were included in each capsule. Abidov et al¹⁷² found evidence to support a role for a proprietary product containing brown seaweed fucoxanthin, n-3 fatty acids, and punicic acid to exert antiobesogenic effects. Premenopausal woman with nonalcoholic fatty liver disease and premenopausal women with normal liver fat who consumed the fucoxanthin product over 16 weeks showed a significant reduction in body weight, by 5.5 kg and 5 kg, respectively, compared with the placebo group. Furthermore, statistically significant improvements in liver fat content, systolic and diastolic blood pressure, and C-reactive protein were observed in both cohorts that consumed the fucoxanthin product, but not in the placebo group, while significantly reduced waist circumference and serum triglycerides were observed only in the intervention group with non-alcoholic fatty liver disease. Interpretation of the role of fucoxanthin in this study is confounded by the additional components (omega-3 fatty acids, punicic acids derived from pomegranate seed oil) present in the treatment, and thus further study is needed to verify the effects of fucoxanthin alone.

More research in healthy human participants is needed to determine whether fucoxanthin plays a role in altering lipid metabolism or in reducing the risk of obesity. Other carotenoids present in red seaweeds, such as lutein, β -carotene, and zeaxanthin, as well as carotenoids present in green seaweeds, such as lutein, β -carotene, echinenone, violaxanthin, and neoxanthin, warrant investigation for their potential antiobesogenic, antidiabetic, or antioxidant bioactivities.^{33,48,173–175}

As with polyphenols, cost-effective and scalable extraction protocols must be developed to produce

quantities of fucoxanthin sufficient to assess bioactive efficacy and mechanisms of action in clinical trials and to assess prospective applications as food ingredients or in supplements.

Micronutrients

Several studies indicate that seaweed consumption contributes to dietary mineral intake,^{1,176} and a higher intake of foods containing seaweed has been associated with sufficient calcium intake to prevent osteoporosis in Korean postmenopausal women.¹⁷⁷ In contrast, 1 report indicates no meaningful contribution to dietary intakes of sodium, potassium, magnesium, phosphorus, calcium, iron, manganese, zinc, selenium, or copper when considering a daily portion of 5 g (dry weight) of 17 brown seaweed and 17 red seaweed food products sourced from China, Japan, and South Korea.¹⁷⁸ This suggests wide differences in mineral content between sources, as shown by the data presented in Tables S9, S10, and S11 in the Supporting Information online.

Seaweed may be an important source of iron, as *Sargassum* spp are reported to contain 156.9 mg of iron per 100 g of dry weight, and the addition of this seaweed to both wheat- and maize-based bread increased the proportion of absorbed iron.¹⁷⁹ Elsewhere, *Sargassum* spp improved iron absorption from a rice meal, with the iron content of the *Sargassum* spp used ranging from 81 to 290 mg/100 g of dry weight over 12 months (highest iron content in July, and lowest content in January).¹⁸⁰

Seaweeds are also considered a rich source of magnesium, but the bioaccessibility of magnesium varies between seaweeds. The magnesium content of *Ulva pertusa*, *Laminaria japonica*, and *Gloiopeltis furcata* is 10.47 mg/kg (41.8% bioaccessible), 6.55 mg/kg (60.8% bioaccessible), and 8.18 mg/kg (72.5% bioaccessible), respectively, under simulated gastrointestinal conditions.¹⁸¹ A subsequent mouse study found that magnesium from *Laminaria japonica* was absorbed most efficiently, which indicates that magnesium intake from seaweed will vary between sources.

Vitamins

Multivitamin supplements are commonly used in the general population to achieve recommended daily intakes, but seaweeds may represent an abundant source of both fat- and water-soluble vitamins, as outlined in Tables S12, S13, and S14 in the Supporting Information online. For example, the vitamin A content (retinol equivalents of carotenoid content, determined by high-performance liquid chromatography) of a 5-g portion of dried seaweed varies from 14.5 μ g (2% of

Reference Nutrient Intake [RNI]) in *Ulva rigida*⁵³ to 70.5 μg in *Fucus spiralis* (10% of RNI).²⁶ The vitamin C content varies from 0.41 mg (1% of RNI) in *Ascophyllum nodosum* to 9.24 mg (23% of RNI) in *Undaria pinnatifida*.¹ Reported folate (vitamin B₉) content varies from 7.5 μg (3.75% of RNI) in *Ulva* spp¹ to 5400 μg (2700% of RNI) in *Ulva rigida*.⁵³ Both seasonal and geographical variations may explain such wide variation within the same genus.

Only 1 study to date has analyzed the vitamin D₃ content of seaweeds, reporting amounts of 0.83 mg/100 g of dry weight in *Fucus spiralis* and 1.05 mg/100 g of dry weight in *Porphyra* spp.²⁶ This equates to 41.5 μg (415% of RNI) and 63.5 μg (635% of RNI) in a 5-g dried portion of *Fucus spiralis* and *Porphyra* spp, respectively.¹⁸² Further characterization studies are required to corroborate these findings, which suggest seaweed is a valuable dietary source of vitamin D.

Seaweed is one of the few nonanimal sources of vitamin B₁₂. *Enteromorpha* spp and *Porphyra* spp are reported to contain 63.58 μg and from 32.26¹⁸³ to 133.8 μg ¹⁸⁴ per 100 g of dry weight, respectively. This equates to 3.18 μg (212% of RNI) and from 1.6 μg (107% of RNI) to 6.69 μg (446% of RNI) in a 5-g dried portion of *Enteromorpha* spp and *Porphyra* spp, respectively. Other studies reporting the vitamin B₁₂ content of seaweeds do not specify whether the vitamin B₁₂ is present in the active form that can be absorbed and utilized in humans. Seaweeds containing active vitamin B₁₂ may be useful for individuals following a vegan diet, who are at risk of vitamin B₁₂ deficiency.¹⁸⁵ For example, the authors of a cohort study in children following a vegan diet for 4 to 10 years attributed healthy vitamin B₁₂ status to nori consumption (*Porphyra* spp).¹⁸⁶ Other seaweeds examined in this study, such as hijiki, wakame, and kombu, are understood to contain limited amounts of vitamin B₁₂ or to contain vitamin B₁₂ analogs that, because of structural differences, do not have vitamin B₁₂ activity in humans.¹⁸⁷ It has also been reported that the drying of *Porphyra* spp inactivates vitamin B₁₂; therefore, processing methods may impact vitamin bioavailability.¹⁸⁸

In summary, seaweeds are a source of both fat- and water-soluble vitamins. Seaweed consumption may improve vitamin status; however, characterization of the vitamin content of seaweed is required to improve the development of seaweed supplements, as vitamin content varies with seaweed species, time of harvesting, and geographical location. Moreover, only a limited number of studies in humans, with few participants, have investigated the bioavailability and activity of vitamins obtained from seaweeds.

Salt

According to the assessment of dietary sodium in the UK National Diet and Nutrition Survey, adults aged 19 to 64 years consume, on average, 7.8 g, 8.0 g, and 8.6 g of salt per day in Scotland, England, and Northern Ireland, respectively, intakes that far exceed the RNIs for salt (6 g/d) and sodium (1.6 g/d).¹⁸⁹ Of the dried seaweed products shown in Tables S1 and S2 in the Supporting Information online, *Laminaria digitata* and *Palmaria palmata* have a ratio of sodium to potassium that may be favorable for their application as condiments to replace salt (1.03 and 0.84, respectively).²⁹ However, small portion sizes of seaweed may be required to prevent excessive salt intake, given that a 5-g portion of *Laminaria digitata* can provide up to 0.35 g of salt and 0.26 g of sodium, while *Palmaria palmata* may provide up to 0.27 g of salt and 0.15 g of sodium. These amounts exceed salt and sodium quantities in an equivalent amount of bacon (0.144 g of salt and 0.0575 g of sodium), which is considered a high-salt food.¹⁹⁰

Iodine

Iodine is a trace element required for the synthesis and function of triiodothyronine (T3) and thyroxine (T4) thyroid hormones. In Japan, where approximately 20 different types of seaweed are consumed, the majority being wakame (*Undaria* spp), kombu (*Laminaria* spp), and nori (*Porphyra* spp), iodine intake varies from 0.1 to 20 mg/d (average intake, 1–3 mg/d), which can exceed the upper tolerable limits of 600 $\mu\text{g}/\text{d}$ (EFSA) and 1100 $\mu\text{g}/\text{d}$ (World Health Organization).^{191–193}

The epidemiological evidence detailing the risks and benefits of iodine intake from seaweeds remains inconclusive. Seaweed consumption was associated with increased risk of papillary carcinoma of the thyroid in Japanese postmenopausal women but not premenopausal women.¹⁹⁴ However, another study found no association between seaweed consumption and total thyroid cancer risk or papillary carcinoma in premenopausal or postmenopausal women.¹⁹⁵ Iodine-induced hypothyroidism is reported in iodine-sufficient, kelp-consuming populations of Japan,¹⁹⁶ yet iodine-induced hyperthyroidism is also reported in individuals who consume kelp.^{197,198} The use of seaweed supplements is not recommended for pregnant women, owing to the variability and excessive iodine content of seaweeds, with kelp-based products being of particular concern.^{199,200} Synergy between iodine supplementation and exposure to heavy metals in seaweed, such as mercury, may also impair thyroid function through the reduction of total T3.²⁰¹

The iodine content of the seaweeds shown in Tables S9, S10, and S11 in the Supporting Information online ranges from 0.06 mg/100 g of dry weight (*Ulva lactuca*) to 624.5 mg/100 g of dry weight (*Laminaria digitata*), but many characterization studies do not quantify iodine. Desideri et al¹⁷⁶ found that 3.3 g of *Laminaria digitata* would provide 4017% of the tolerable daily intake for iodine and suggested that habitual intake of seaweed with an iodine content exceeding 45 mg/kg of dry weight could impair thyroid function. Given that *Laminaria* spp are widely abundant, currently used as food ingredients, and have such a high iodine content, characterization of iodine in *Laminaria*-containing products is warranted. In contrast, a 5-g portion of *Porphyra tenera* is reported to provide only 80 µg of iodine.²⁰²

Static in vitro digestion studies have reported the bioavailability of iodine in seaweed as follows: *Laminaria* spp (17%–28%), *Sargassum fusiforme* (12%), *Palmaria palmata* (10%), *Undaria pinnatifida* (2%–12%), *Himanthalia elongata* (4%), *Porphyra* spp (5%), *Ulva rigida* (2%), and cooked *Himanthalia elongata* and *Sacchoriza polyschides* (below the limit of detection).^{203,204} Boiling has been shown to reduce the iodine content of *Alaria esculenta* (from 670 µg/g to 165 µg/g), *Palmaria palmata* (97 µg/g to 66 µg/g), and *Ulva intestinalis* (92 µg/g to 79 µg/g), information that may be beneficial for industry to provide to consumers.²⁰⁴

In humans, urinary excretion of iodine following *Ascophyllum nodosum* ingestion was reported as only 33% (excretion of potassium iodide control = 59%).²⁰⁵ The reduced iodine bioavailability was attributed to reduced release of iodine from the seaweed food matrix (ie, iodine bound to proteins, polysaccharides, polyphenols, and pigments). In a Caco-2 and HT29-MTX coculture, iodine uptake following in vitro digestion was only 4% to 6% (hijiki), 2% to 4% (kombu), and 4% to 7% (wakame),²⁰³ which also suggests limited liberation of iodine species, limited solubility of iodine, or limited absorption of iodine.^{206–208}

Urinary excretion of iodine from *Gracilaria verrucosa* and *Laminaria hyperborea* was reported as 101% and 90%, respectively, in an iodine-sufficient population, yet as 85% and 61.5% in an iodine-deficient population.²⁰⁹ Reduced urinary iodine excretion in the deficient cohort was attributed to increased iodine storage in the thyroid²¹⁰; thus, seaweed consumption may improve iodine status in those at risk of iodine deficiency, as demonstrated in vegan populations.^{211,212}

Iodine absorption from *Laminaria japonica* is estimated as 57% to 71%, although serum thyroid-stimulating hormone (TSH) was significantly increased above the normal limits in 4 of 6 participants who consumed 15 g of *Laminaria japonica* daily for 7 to 10 days,

in 4 of 14 who consumed 30 g/d for 7 to 10 days, and in 1 of 3 who consumed 15 g/d for 55 to 87 days.²¹³ These findings corroborate previous evidence that kelp supplementation increased serum TSH over 4 weeks.²¹⁴ Urinary iodide excretion increased 30-fold and 44-fold from baseline (in subgroups that received 15 g and 30 g, respectively), but returned to baseline 7 to 40 days after seaweed consumption ceased. Furthermore, iodine intake was improved without compromising thyroid function when 500 mg of *Ascophyllum nodosum* containing 356 µg of iodine was given to healthy women for 14 days.²¹⁵ Urinary iodine concentrations increased significantly, reflecting sufficient intake and subsequent renal excretion. Plasma concentrations of T3, T4, free T3, and free T4 were unchanged between pre- and post-intervention, while serum TSH increased significantly, albeit within the normal range.

Some have suggested that future human intervention studies should quantify the iodine content of a seaweed food ingredient or supplement during product development, so that urinary iodine concentrations could be measured as a biomarker of iodine intake and bioavailability at time points throughout interventions.^{216,217}

Strategies to prevent excessive iodine intake from seaweed food products include the disclosure of iodine content and the provision of cooking instructions on product labeling. Disclosure of iodine content on food labeling was reported for only 22 of 224 seaweed-containing food products on sale in the United Kingdom, while estimated content was provided for 40 products.⁴ Some 26 products had the potential to provide iodine in excess of the tolerable upper intake level of 600 µg/d when serving suggestions were applied, but for the remaining 162, this was unknown. Guidance about an individual's iodine status and how seaweed consumption may benefit the individual could also ensure consumer safety.

The myriad variations in iodine concentration between seaweed species, season, and harvest location present challenges to the food industry, since there is limited and conflicting information about how individual seaweeds may impact iodine status and thyroid health.

Heavy metals

One concern about seaweed consumption is exposure to heavy metals such as arsenic, aluminum, cadmium, lead, rubidium, silicon, strontium, and tin.¹⁷⁶ The contamination of seaweeds with heavy metals depends on habitat or ecology, which has led to inconsistency in research findings. Seaweeds growing in areas of contamination, often caused by industry or poor sewage

systems, accumulate heavy metals from the surrounding water and rocks, but at levels that pose little risk to human health.²¹⁸ However, exposure to contaminants is increased in perennial seaweeds, the regular consumption of which may lead to risk of heavy metal toxicity in humans.^{219,220} Levels of arsenic, mercury, lead, and cadmium in 426 Korean dried seaweed products ranged from 0.2% to 6.7% of provisional tolerable weekly intakes when 8.5 g of seaweed was consumed per day.^{176,218,221} In 1 study, the authors called for continuous monitoring of heavy metals in seaweed-based food products, owing to differences between species in the bioabsorption of metals.²²¹ An example of these between-species differences is evident in *Laminaria* spp. At an intake of 3.3 to 12.5 g/d, *Laminaria digitata* contains 24 to 90 µg of cadmium,¹⁷⁶ which corresponds to 40% to 150% of the tolerable daily intake, while *Laminaria japonica* contains 0.45 to 0.80 mg/kg, which exceeds the maximum limits for seaweed products according to legislation in France (0.5 mg/kg of dry weight) and Australia/New Zealand (0.2 mg/kg of dry weight), but not in China (1.0 mg/kg).²²⁵ Tables S15, S16, and S17 in the Supporting Information online provide details of the heavy metal content of several brown, red, and green seaweeds, respectively, although information about the toxicokinetics of heavy metals ingested from seaweeds is too limited to make conclusions about potential health risks.

In a cross-sectional study of heavy metal concentrations in 3404 healthy Korean adults, urinary arsenic concentrations were significantly increased in both the second and third tertiles of seaweed consumption.²²⁶ Arsenic species were not determined in this study, but blood mercury was significantly higher in the highest consumers of seaweed versus the lowest consumers. Preliminary research shows that increased water temperatures can increase mercury absorption by fish, and the same biosorption of mercury may occur in seaweed.²²⁷ Considering global warming, trends in the heavy metal content of seaweed should also be monitored; likewise, the presence of rare earth elements, recently identified in northwest Mediterranean seaweeds, should be watched.²²⁸ The placental transfer of heavy metals from mother to fetus can cause neurological, developmental, and endocrine disorders in infants.^{230,231} Ultimately, the extraction of bioactive or nutritional components from seaweeds may mitigate ingestion of excessive heavy metals, which can be mutagenic and carcinogenic to humans.²²⁹

Arsenic

A major consideration for the exploitation of seaweeds as health foods or functional food ingredients is the

need to speciate and quantify the levels of arsenic present in seaweed products. Arsenic species may be categorized as toxic (inorganic arsenic, which are class I carcinogens), nontoxic (arsenobetaine), or potentially toxic (fat-soluble arsenic, arsenosugars, and other organoarsenicals).²³² The health risks associated with inorganic hydrogen arsenate species are related to DNA damage, which predisposes cells to carcinogenesis. Consumption of inorganic arsenic has been shown to increase the incidence of lung, bladder, skin, and kidney cancers and has also been linked to skin lesions, cardiovascular disease, neurological effects, and diabetes.^{233–235}

Most arsenic species in seaweeds are arsenosugars, typically ligated to glycerol, sulfonate, or phosphonate. Arsenosugars resist degradation in the stomach and, upon entering the lower gastrointestinal tract, are metabolized to at least 12 different metabolites, including dimethylarsinate, methylarsinate, and dimethylarsinoyl ethanol, but the toxicity of these metabolites is unknown.^{232,236–238}

Speciation and concentration of arsenic in brown seaweeds (*Ascophyllum nodosum*, *Laminaria digitata*, *Fucus vesiculosus*, *Fucus spiralis*, *Alaria esculenta*, and *Saccharina latissima*),^{239,240} red seaweeds (*Porphyra umbilicalis*, *Chondrus crispus*, *Gracilaria vermiculophylla*, and *Palmaria palmata*), and green seaweeds (*Ulva prolifera* and *Ulva lactuca*)²⁴⁰ revealed that total arsenic content ranged from 4.1 to 111.0 µg/g, with the majority of arsenic present as arsenosugars (inorganic arsenic content was < 1.0 µg/g). The exception was *Laminaria digitata*, which contained inorganic arsenic at levels of 2.8 to 20.0 µg/g (USA)²⁴⁰ and 2.2 to 87.0 µg/g (Ireland).²³⁹ These levels represent a large proportion of the total arsenic content of *Laminaria digitata*, reported to range from 36.0 to 131.0 µg/g of dry weight.^{176,239,240} In contrast, *Laminaria japonica* sourced from China contained inorganic arsenics at a concentration of 0.16 to 0.58 mg/kg, which is below maximum limits set by China (1.0 mg/kg of dry weight),²²⁵ France (3.0 mg/kg of dry weight),²⁴¹ and Australia/New Zealand (1.0 mg/kg of dry weight).²⁴² Such variation in inorganic arsenic contents may warrant regular testing for inorganic arsenic content in *Laminaria* spp food products.

Another recent study reported that the content of inorganic arsenic was negligible in 23 seaweed food products except for hijiki (19.83 µg/g), agar (0.06 µg/g), and nori (0.03 µg/g).²³⁵ Total arsenic concentrations in seaweed products were as follows, in descending order: hijiki (83.7 µg/g), kombu (51.2 µg/g), kelp seasoning (43.5 µg/g), arame (41.6 µg/g), wakame (34.7 µg/g), dried red seaweed (35.2 µg/g), nori (19.4 µg/g), dulse (12.1 µg/g), agar (0.23 µg/g), and kelp noodles (0.08 µg/g).

The amount of inorganic arsenic in 112 edible seaweed products sold in Spain was also within safe limits, with the exception of hijiki, in which the level of inorganic arsenic ranged from 41.6 to 117.0 $\mu\text{g/g}$.²⁴³

Inclusion of 3% hijiki powder has caused arsenic poisoning in rats,²⁴⁹ and the risk of hijiki to public health has led to current recommendations against the consumption of hijiki in Asia,²⁴⁴ Australia,²⁴⁶ Europe,^{245,247,248} and the United States.²⁴⁶ Seaweeds such as arame, wakame, kombu, and nori, however, are suggested as safe to eat because they contain inorganic arsenic at a concentration of less than 0.3 $\mu\text{g/g}$, which is encouraging for potential food ingredient applications.²⁵⁰

The amounts of potentially bioaccessible arsenite, arsenate, methylarsonate, and dimethylarsinate following the *in vitro* digestion of *Laminaria japonica*, *Undaria pinnatifida*, *Hizikia fusiformis*, *Porphyra yezoensis*, and *Enteromorpha prolifera* were low enough to indicate no hazard of inorganic arsenic to human health.²⁵¹ However, cooking of *Porphyra* spp and *Hizikia fusiforme* by baking and boiling, respectively, has been shown to increase inorganic arsenic species,²⁵² while soaking, cooking, boiling, and washing/soaking of other seaweeds reduced total arsenic by up to 58.8%, 91.5%, 50%, and 60%, respectively.²⁵³

Wei et al²⁵⁴ investigated the bioavailability of arsenic from *Porphyra* spp, reporting that total urinary arsenic peaked (average, 92.5 ng/mL) after 20 to 30 hours, resulting in a 20-fold increase in DMA before returning to normal levels after 80 hours. Another study showed that 2 arsenic metabolites, DMA and 2-dimethylarsinoethyl ethanol (DMAE), were detected in the urine of 5 volunteers who consumed 20 to 25 g of *Laminaria* spp (total arsenic, 43.2 $\mu\text{g/g}$): the peak ratio of arsenic to creatinine was 228, 158, 141, 72, and 70 ng/mL, and levels normalized after 80 hours.²³⁶

Consumption of 10 g of nori, kombu, or wakame per day for 3 days, followed by a 3-day washout period between seaweeds, resulted in increased levels of the arsenosugars DMA, thio-dimethylarsenoacetic acid (DMAA), and thio-DMAE in 24-hour urine samples obtained during the 3 days of seaweed consumption. The extent of these increases varied between seaweeds and individuals.²³⁵ Toxic thio-DMA was present only at trace levels, and the authors identified thio-DMAE and thio-DMAA as unique arsenosugar metabolites that could potentially be used as urinary biomarkers for dietary intake of arsenic from seaweeds.

The arsenosugars present in seaweed resist cooking and *in vitro* digestion processes and have been suggested to be absorbed, in part, into the hepatic portal system intact.²⁵⁵ Human studies have shown considerable differences in the rate of excretion of arsenosugars,

ranging from 4% to 95%.²⁵⁶ The high variability associated with arsenosugar metabolism may be attributable to between-individual differences in endogenous digestion, gut microbiota composition and activity, passage across the intestinal barrier, or transformation in the liver.²⁵⁶ Thus, there is a need to characterize the metabolic fate of arsenosugars in order to clarify the safety associated with arsenosugar-rich seafoods.²⁵⁷

While regulatory bodies have attempted to provide guidance about arsenic intake, there is a need for clearer regulation and guidance regarding the permissible arsenic content of foods. For example, the UK Food Standards Agency has advised against consuming *Sargassum fusiforme* (hijiki) because of significant food safety concerns over high levels of inorganic arsenic.²⁴⁸ To reduce health risks, regular environmental assessment and analysis of the arsenic species present in seaweed-containing food products may be required to ascertain the exposure to and the potential toxicity of heavy metals.^{221,242} Indirect exposure to arsenic could also be a concern if arsenic accumulates in the food chain following the use of seaweed either as feed for livestock²⁵⁸ or as fertilizer.²⁵⁹ The majority of edible seaweeds have been reported to contain heavy metals in safe amounts. As with iodine, it has been suggested that food regulation should ensure the disclosure of heavy metal contents on food labeling and establish legal limits for the content of inorganic arsenic in seaweed.²⁶⁰ Cooking methods and food processing procedures may help reduce the amount of heavy metal present in edible seaweeds, but regulatory bodies and industry both face challenges. For regulatory bodies, the greatest challenge in developing safe limits is the interindividual differences in biotransformation, metabolism, and excretion of arsenic, while for industry, the greatest challenge is the high within-species variability of arsenic levels in seaweed and the potential costs of regularly monitoring product(s).

HEALTH IMPACT OF HABITUAL INTAKE OF WHOLE SEAWEEDS

While this review highlights the lack of human intervention trials investigating the potential risks and benefits of consuming seaweed components, some observational evidence does exist. Epidemiological evidence indicates that seaweed-containing diets are inversely associated with all-cause mortality and cardiovascular disease mortality in Japanese adults.²⁶¹ On the other hand, Korean men with metabolic syndrome are reported to consume significantly more seaweed than those without metabolic syndrome, although no mechanistic insight has been published.²⁶²

Consumption of *Porphyra* spp was inversely associated with breast cancer risk in premenopausal women but not in postmenopausal women, and no association was found between *Undaria pinnatifida* consumption and breast cancer risk.²⁶⁵ A study by Michikawa et al¹⁹⁴ identified a positive association between seaweed consumption and the risk of thyroid cancer (especially papillary carcinoma) in postmenopausal women, while Wang et al¹⁹⁵ did not find an association between seaweed intake and thyroid cancer incidence in either premenopausal or postmenopausal women. Case-controlled studies by Hoshiyama et al^{266,267} implicated an inverse relationship between seaweed consumption and stomach and colon cancer; nevertheless, interpretation warrants caution in light of the low sample power of the studies.

An inverse association was also reported between *Undaria pinnatifida*, *Sargassum fusiforme*, and *Porphyra* spp intake and prevalence of allergic rhinitis in pregnant Japanese women (n = 1002).²⁶⁸ The study did not measure iodine intake or iodine status, which would have contributed to the knowledge of iodine intake from seaweeds during pregnancy, since current recommendations in Australia and New Zealand limit brown seaweed intake to 1 portion per week in pregnant women.²⁶⁹ There are also concerns about the potential for seaweed to contribute to foodborne infections, as noted by reports of norovirus contamination of *Enteromorpha* spp²⁷⁰ and the presence of polycavernoside A toxin in *Gracilaria edulis*.^{271,272}

Current Asian populations are reported to consume less seaweed than previous generations, shifting toward a high-energy, low-fiber Westernized diet that promotes the development of metabolic syndrome and has increased the number of iodine-deficient individuals in Japan.^{273,274} One recent intervention study in a European population concluded that *Palmaria palmata* consumption could improve iodine status in adults, as serum TSH was significantly increased (within the normal clinical range) following *Palmaria palmata* intake of 5 g/d for 28 days.²⁷⁵ The authors of this study highlighted the need to characterize seaweed composition when undertaking human interventions to help ascertain which components of seaweed affect health, immune function, and disease risk. While the evidence from observational studies reviewed here may indicate potential benefits, the outcomes must be viewed with considerable caution. Randomized controlled trials with suitable biomarkers, as well as supportive in vitro and in vivo animal studies, are warranted to verify previous observations and elucidate the mechanisms of action of edible seaweeds in humans.

CONCLUSION

Edible seaweeds are a rich and sustainable source of macronutrients (particularly dietary fiber) and

micronutrients, but if seaweeds are to contribute to future global food security, legislative measures to ensure monitoring and labeling of food products are needed to safeguard against excessive intakes of salt, iodine, and heavy metals.

While heavy metal concentrations in edible seaweeds are generally below toxic levels, bioaccumulation of arsenic is a risk, and more studies of heavy metal toxicokinetics are needed. A trade-off between iodine and/or heavy metal ingestion and the amount of whole seaweed needed to obtain meaningful amounts of PUFAs, protein, or dietary fiber may limit the recommended portion size. Therefore, the extraction of individual components from the complex seaweed matrix is a legitimate strategy to create added-value products, particularly since novel bioactive components extracted from seaweeds are increasingly studied as potential agents to combat noncommunicable diseases.

Looking ahead, more human intervention studies with defined health-related endpoints are needed to establish how chronic consumption of whole seaweeds and their extracted bioactive components affects human health. Mechanisms of action must also be elucidated to substantiate any future health claims associated with seaweed consumption and to support applications within the food and nutraceutical industries.

Acknowledgments

Author contributions. All authors (P.C., C.O'H., P.J.M., E.M.M., and P.J.A.) contributed significantly to the work's conception, design, and interpretation. P.C. and C.O'H. performed the data collection. All authors participated in the writing and critical revision of the manuscript in a manner sufficient to establish ownership of the intellectual content. All authors read and approved the version of the manuscript submitted.

Funding/support. This review was funded by the Department of Agriculture, Food and the Marine (DAFM) under Ireland's National Development Plan 2007–2013, via The PreMara Project, project no. 13F511. P.C. is a recipient of a Department for Employment and Learning Northern Ireland (DELNI) postgraduate studentship. C.O'H. is undertaking an InterTradeIreland FUSION program between Ulster University and VOYA Products Ltd.

Declaration of interest. C.O'H. is an employee of VOYA Products Ltd. The remaining authors have no relevant interests to declare.

Supporting Information

The following Supporting Information is available through the online version of this article at the publisher's website.

Table S1 Nutritional information for a selection of seaweed products sold throughout the United Kingdom and the Republic of Ireland

Table S2 Nutritional information for a selection of seaweed products sold throughout the United Kingdom and the Republic of Ireland

Table S3 Amino acid content of brown seaweeds

Table S4 Amino acid content of red seaweeds

Table S5 Amino acid content of green seaweeds

Table S6 Lipid content of brown seaweeds

Table S7 Lipid content of red seaweeds

Table S8 Lipid content of green seaweeds

Table S9 Essential minerals present in brown seaweeds

Table S10 Essential minerals present in red seaweeds

Table S11 Essential minerals present in green seaweeds

Table S12 Vitamin content of brown seaweeds

Table S13 Vitamin content of red seaweeds

Table S14 Vitamin content of green seaweeds

Table S15 Heavy metal content of brown seaweeds

Table S16 Heavy metal content of red seaweeds

Table S17 Heavy metal content of green seaweeds

REFERENCES

1. MacArtain P, Gill CI, Brooks M, et al. Nutritional value of edible seaweeds. *Nutr Rev*. 2007;65:535–543.
2. Rebours C, Marinho-Soriano E, Zertuche GJA, et al. Seaweeds: an opportunity for wealth and sustainable livelihood for coastal communities. *J Appl Phycol*. 2014;26:1939–1951.
3. Lange KW, Hauser J, Nakamura Y, Kanaya S. Dietary seaweeds and obesity. *Food Sci Hum Wellness*. 2015;4:87–96.
4. Bouga M, Combet E. Emergence of seaweed and seaweed-containing foods in the UK: focus on labeling, iodine content, toxicity and nutrition. *Foods*. 2015;4:240–253.
5. Collins KG, Fitzgerald GF, Stanton C, Ross RP. Looking beyond the terrestrial: the potential of seaweed derived bioactives to treat non-communicable diseases. *Mar Drugs*. 2016;14:60. doi:10.3390/md14030060
6. Postma PR, Cerezo-Chinarro O, Akkerman RJ, et al. Biorefinery of the macroalgae *Ulva lactuca*: extraction of proteins and carbohydrates by mild disintegration. *J Appl Phycol*. 2018;30:1281–1293.
7. MacMonagail M, Cornish L, Morrison L, et al. Sustainable harvesting of wild seaweed resources. *Eur J Phycol*. 2017;52:371–390.
8. Holdt SL, Kraan S. Bioactive compounds in seaweed: functional food applications and legislation. *J Appl Phycol*. 2011;23:543–597.
9. Suleria HA, Osborne S, Masci P, Gobe G. Marine-based nutraceuticals: an innovative trend in the food and supplement industries. *Mar Drugs*. 2015;13:6336–6351.
10. Food and Agriculture Organization of the United Nations. The State of World Fisheries and Aquaculture. *Contributing to Food Security and Nutrition for All*. Rome, Italy: Food and Agriculture Organization of the United Nations; 2016. Document no. IS555.
11. South African Government, Department of Agriculture, Forestry and Fisheries. Policy on the allocation and management of commercial fishing rights in the seaweed fishery: 2015. <https://www.informea.org/sites/default/files/legislation/saf150531.pdf>. Government Gazette No. 39417. Published November 16, 2015. Accessed December 20, 2018.
12. European Commission. Commission Regulation (EC) No 710/2009 of 5 August 2009 amending Regulation (EC) No 889/2008 laying down detailed rules for the implementation of Council Regulation (EC) No 834/2007, as regards laying down detailed rules on organic aquaculture animal and seaweed production. <https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:204:0015:0034:EN:PDF>. Published August 5, 2009. Accessed December 20, 2018.
13. Ministry of Natural Resources, Republic of the Philippines. Rules and regulations governing the gathering and farming of seaweeds. Diliman, Quezon City, the Philippines: Bureau of Fisheries and Aquatic Resources; 1983. Order no. 146.
14. Kraan S. Mass-cultivation of carbohydrate rich macroalgae, a possible solution for sustainable biofuel production. *Mitig Adapt Strateg Glob Change*. 2013;18:27–46.
15. European Commission. Novel food catalogue. Version 1.1. Brussels, Belgium: European Commission. https://ec.europa.eu/food/safety/novel_food/catalogue_en. Accessed February 6, 2018.
16. Madden M, Mitra M, Ruby D, Schwarz J. Seasonality of selected nutritional constituents of edible Delmarva seaweeds. *J Phycol*. 2012;48:1289–1298.
17. Schiener P, Black KD, Stanley MS, Green DH. The seasonal variation in the chemical composition of the kelp species *Laminaria digitata*, *Laminaria hyperborea*, *Saccharina latissima* and *Alaria esculenta*. *J Appl Phycol*. 2015;27:363–373.
18. Soares C, Machado S, Vieira EF, et al. Seaweeds from the Portuguese coast: a potential food resource? *IOP Conf Ser Mater Sci Eng*. 2017;231:012126.
19. Maehre HK, Malde MK, Eilertsen KE, Elvevoll EO. Characterization of protein, lipid and mineral contents in common Norwegian seaweeds and evaluation of their potential as food and feed. *J Sci Food Agric*. 2014;94:3281–3290.
20. Tabarsa M, Rezaei M, Ramezani Z, et al. Fatty acids, amino acids, mineral contents, and proximate composition of some brown seaweeds. *J Phycol*. 2012;48:285–292.
21. El-Said GF, El-Sikaily A. Chemical composition of some seaweed from Mediterranean Sea coast, Egypt. *Environ Monit Assess*. 2013;185:6089–6099.
22. Rohani-Ghadikolaei K, Abdulalan E, Ng WK. Evaluation of the proximate, fatty acid and mineral composition of representative green, brown and red seaweeds from the Persian Gulf of Iran as potential food and feed resources. *J Food Sci Technol*. 2012;49:774–780.
23. Smith JL, Summers G, Wong R. Nutrient and heavy metal content of edible seaweeds in New Zealand. *New Zeal J Crop Hort*. 2010;38:19–28.
24. Ortiz J, Romero N, Robert P, et al. Dietary fiber, amino acid, fatty acid and tocopherol contents of the edible seaweeds *Ulva lactuca* and *Durvillaea antarctica*. *Food Chem*. 2006;99:98–104.
25. Mišurcová L, Křáčmar S, Klejdus B, Vacek J. Nitrogen content, dietary fiber, and digestibility in algal food products. *Czech J Food Sci*. 2010;28:27–35.
26. Paiva L, Lima E, Patarra RF, et al. Edible Azorean macroalgae as source of rich nutrients with impact on human health. *Food Chem*. 2014;164:128–135.
27. Marsham S, Scott GW, Tobin ML. Comparison of nutritive chemistry of a range of temperate seaweeds. *Food Chem*. 2007;100:1331–1336.
28. Sanchez-Machado DI, Lopez-Cervantes J, Lopez-Hernandez J, Paseiro-Losada P. Fatty acids, total lipid, protein and ash contents of processed edible seaweeds. *Food Chem*. 2004;85:439–444.
29. Rodrigues D, Freitas AC, Pereira L, et al. Chemical composition of red, brown and green macroalgae from Buarcos bay in Central West Coast of Portugal. *Food Chem*. 2015;183:197–207.
30. Matanjun P, Mohamed S, Mustapha NM, Muhammad K. Nutrient content of tropical edible seaweeds, *Eucheuma cottonii*, *Caulerpa lentillifera* and *Sargassum polycystum*. *J Appl Phycol*. 2009;21:75–80.
31. Marinho-Soriano E, Fonseca PC, Carneiro MAA, Moreira WSC. Seasonal variation in the chemical composition of two tropical seaweeds. *Bioresour Technol*. 2006;97:2402–2406.
32. Peng Y, Xie EY, Zheng K, et al. Nutritional and chemical composition and antiviral activity of cultivated seaweed *Sargassum naoshouense* Tseng et Lu. *Mar Drugs*. 2013;11:20–32.
33. Parjikolaie BB, Bruhn A, Eybye K, Larsen M, et al. Valuable biomolecules from nine north Atlantic red macroalgae: amino acids, fatty acids, carotenoids, minerals and metals. *Nat Resour*. 2016;7:157–183.
34. Sakthivel R, Devi KP. Evaluation of physicochemical properties, proximate and nutritional composition of *Gracilaria edulis* collected from Palk Bay. *Food Chem*. 2015;174:68–74.
35. Francavilla M, Franchi M, Monteleone M, Caroppo C. The red seaweed *Gracilaria gracilis* as a multi products source. *Mar Drugs*. 2013;11:3754–3776.
36. Wong KH, Cheung PCK. Nutritional evaluation of some subtropical red and green seaweeds: part I—proximate composition, amino acid profiles and some physico-chemical properties. *Food Chem*. 2000;71:475–482.
37. Siddique MAM. Proximate chemical composition and amino acid profile of two red seaweeds (*Hypnea pannosa* and *Hypnea musciformis*) collected from St. Martin's Island, Bangladesh. *J Fishscim (Turkey)*. 2013;7:178–186. doi:10.3153/jfscm.2013018

38. Fayaz M, Namitha KK, Murthy KNC, et al. Chemical composition, iron bioavailability, and antioxidant activity of *Kappaphycus alvarezii* (Doty). *J Agric Food Chem*. 2005;53:792–797.
39. Kumar KS, Ganesan K, Rao PVS. Seasonal variation in nutritional composition of *Kappaphycus alvarezii* (Doty) Doty—an edible seaweed. *J Food Sci Technol*. 2015;52:2751–2760.
40. Gressler V, Fujii MT, Martins AP, et al. Biochemical composition of two red seaweed species grown on the Brazilian coast. *J Sci Food Agric*. 2011;91:1687–1692.
41. Cian RE, Fajardo MA, Alaiz M, et al. Chemical composition, nutritional and antioxidant properties of the red edible seaweed *Porphyra columbina*. *Int J Food Sci Nutr*. 2014;65:299–305.
42. Cofrades S, Lopez-Lopez I, Bravo L, et al. Nutritional and antioxidant properties of different brown and red Spanish edible seaweeds. *Food Sci Technol Int*. 2010;16:361–370.
43. Nguyen VT, Ueng JP, Tsai GJ. Proximate composition, total phenolic content, and antioxidant activity of seagrass (*Caulerpa lentillifera*). *J Food Sci*. 2011;76:C950–C958.
44. Ratana-Arporn P, Chirapart A. Nutritional evaluation of tropical green seaweeds *Caulerpa lentillifera* and *Ulva reticulata*. *Kasetsart J*. 2006;40(suppl):75–83.
45. Mandlik R, Naik S, Tatiya A. Evaluation of physicochemical properties of seaweed, *Caulerpa racemosa*. *Int J Res Ayurveda Pharm*. 2014;5:540–546.
46. Kokilam G, Vasuki S. Biochemical and phytochemical analysis on *Ulva fasciata* and *Caulerpa taxifolia*. *Int J Pharm Sci Res*. 2014;4:7–11.
47. Aguilera-Morales M, Casas-Valdez M, Carrillo DB, et al. Chemical composition and microbiological assays of marine algae *Enteromorpha* spp. as a potential food source. *J Food Compos Anal*. 2005;18:79–88.
48. Pirian K, Piri K, Sohrabipour J, et al. Nutritional and phytochemical evaluation of the common green algae, *Ulva* spp. (Ulvothyceae), from the Persian Gulf. *Fund Appl Limnol*. 2016;188:315–327.
49. Paiva L, Lima E, Neto AI, et al. Health-promoting ingredients from four selected Azorean macroalgae. *Food Res Int*. 2016;89:432–438.
50. Escobido HRS, Orbita MLS, Orbita RR. Evaluation of the biochemical and phytochemical components of green seaweed *Enteromorpha intestinalis* (Linnaeus) in Initao, Misamis oriental, Mindanao, Philippines. *Int J Biosci*. 2016;9:114–122.
51. Yaich H, Garna H, Besbes S, et al. Chemical composition and functional properties of *Ulva lactuca* seaweed collected in Tunisia. *Food Chem*. 2011;128:895–901.
52. Bikker P, van Krimpen MM, van Wijkelaar P, et al. Biorefinery of the green seaweed *Ulva lactuca* to produce animal feed, chemicals and biofuels. *J Appl Phycol*. 2016;28:3511–3525.
53. Taboada C, Millan R, Miguez I. Composition, nutritional aspects and effect on serum parameters of marine algae *Ulva rigida*. *J Sci Food Agric*. 2010;90:445–449.
54. Harnedy PA, FitzGerald RJ. Bioactive proteins, peptides, and amino acids from macroalgae. *J Phycol*. 2011;47:218–232.
55. Greenwood DA, Kraybill HR, Schweigert BS. Amino acid composition of fresh and cooked beef cuts. *J Biol Chem*. 1951;193:23–28.
56. Lourenço SO, Barbarino E, De-Paula JC, et al. Amino acid composition, protein content and calculation of nitrogen-to-protein conversion factors for 19 tropical seaweeds. *Phycological Res*. 2002;50:233–241.
57. EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific opinion on dietary reference values for protein. *EFSA J*. 2012;10:2557. doi:10.2903/j.efsa.2012.2557
58. Misurcova L, Bunka F, Vavra Ambrozova J, et al. Amino acid composition of algal products and its contribution to RDI. *Food Chem*. 2014;151:120–125.
59. Qasim R. Amino acid composition of some common seaweeds. *Pak J Pharm Sci*. 1991;4:49–54.
60. Galland-Irmouli AV, Fleurence J, Lamghari R, et al. Nutritional value of proteins from edible seaweed *Palmaria palmata* (dulse). *J Nutr Biochem*. 1999;10:353–359.
61. Goñi I, Gudiel-Urbano M, Saura-Calixto F. In vitro determination of digestible and unavailable protein in edible seaweeds. *J Sci Food Agric*. 2002;82:1850–1854.
62. Urbano MG, Goni I. Bioavailability of nutrients in rats fed on edible seaweeds, *Nori* (*Porphyra tenera*) and *Wakame* (*Undaria pinnatifida*), as a source of dietary fibre. *Food Chem*. 2002;76:281–286.
63. Cerna M. Seaweed proteins and amino acids as nutraceuticals. *Adv Food Nutr Res*. 2011;64:297–312.
64. Beasley JM, Shikany JM, Thomson CA. The role of dietary protein intake in the prevention of sarcopenia of aging. *Nutr Clin Pract*. 2013;28:684–690.
65. Maehre HK, Jensen IJ, Eilertsen KE. Enzymatic pre-treatment increases the protein bioaccessibility and extractability in dulse (*Palmaria palmata*). *Mar Drugs*. 2016;14. doi:10.3390/md14110196
66. Kadam SU, Alvarez C, Tiwari BK, O'Donnell CP. Extraction and characterization of protein from Irish brown seaweed *Ascophyllum nodosum*. *Food Res Int*. 2017;99:1021–1027.
67. Harnedy PA, FitzGerald RJ. Extraction of protein from the macroalga *Palmaria palmata*. *Lebensm Wissen Technol*. 2013;51:375–382.
68. Harnedy PA, FitzGerald RJ. Extraction and enrichment of protein from red and green macroalgae. *Methods Mol Biol*. 2015;1308:103–108.
69. Bleakley S, Hayes M. Algal proteins: extraction, application, and challenges concerning production. *Foods*. 2017;6:33.
70. Admassu H, Gasmalla MAA, Yang R, Zhao W. Bioactive peptides derived from seaweed protein and their health benefits: antihypertensive, antioxidant, and antidiabetic properties. *J Food Sci*. 2018;83:6–16.
71. Sato M, Oba T, Yamaguchi T, et al. Antihypertensive effects of hydrolysates of wakame (*Undaria pinnatifida*) and their angiotensin-I-converting enzyme inhibitory activity. *Ann Nutr Metab*. 2002;46:259–267.
72. Jimenez-Escrig A, Gomez-Ordóñez E, Ruperez P. Seaweed as a source of novel nutraceuticals: sulfated polysaccharides and peptides. *Adv Food Nutr*. 2011;64:325–337.
73. Suetsuna K, Maekawa K, Chen JR. Antihypertensive effects of *Undaria pinnatifida* (wakame) peptide on blood pressure in spontaneously hypertensive rats. *J Nutr Biochem*. 2004;15:267–272.
74. Fitzgerald C, Aluko RE, Hossain M, et al. Potential of a renin inhibitory peptide from the red seaweed *Palmaria palmata* as a functional food ingredient following confirmation and characterization of a hypotensive effect in spontaneously hypertensive rats. *J Agric Food Chem*. 2014;62:8352–8356.
75. Harnedy PA, O'Keeffe MB, FitzGerald RJ. Fractionation and identification of antioxidant peptides from an enzymatically hydrolysed *Palmaria palmata* protein isolate. *Food Res Int*. 2017;100:416–422.
76. Cian RE, Garzon AG, Ancona DB, et al. Chelating properties of peptides from red seaweed *Pyropia columbina* and its effect on iron bio-accessibility. *Plant Foods Hum Nutr*. 2016;71:96–101.
77. Harnedy PA, O'Keeffe MB, FitzGerald RJ. Purification and identification of dipeptidyl peptidase (DPP) IV inhibitory peptides from the macroalga *Palmaria palmata*. *Food Chem*. 2015;172:400–406.
78. Probst L, Frideres L, Pedersen B, Amato F. *Sustainable Safe, and Nutritious Food: New Nutrient Sources*. Brussels, Belgium: European Commission; 2015.
79. EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific opinion on dietary reference values for carbohydrates and dietary fibre. *EFSA J*. 2010;8:1462. doi:10.2903/j.efsa.2010.1462
80. Scientific Advisory Committee on Nutrition. *Carbohydrates and Health*. London, UK: TSO (The Stationery Office); 2015.
81. Clark MJ, Slavin JL. The effect of fiber on satiety and food intake: a systematic review. *J Am Coll Nutr*. 2013;32:200–211.
82. EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific opinion on the substantiation of health claims related to dietary fibre pursuant to Article 13(1) of Regulation (EC) No 1924/2006. *EFSA J*. 2010;8:1735. doi:10.2903/j.efsa.2010.1735
83. EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific opinion on the substantiation of health claims related to the replacement of mixtures of saturated fatty acids (SFAs) as present in foods or diets with mixtures of monounsaturated fatty acids (MUFAs) and/or mixtures of polyunsaturated fatty acids (PUFAs), and maintenance of normal blood LDL-cholesterol concentrations (ID 621, 1190, 1203, 2906, 2910, 3065) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. *EFSA J*. 2011;9:18. doi:10.2903/j.efsa.2011.2069
84. Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. *Nat Rev Gastroenterol Hepatol*. 2017;14:491–502.
85. Brownlee IA, Allen A, Pearson JP, et al. Alginate as a source of dietary fiber. *Crit Rev Food Sci Nutr*. 2005;45:497–510.
86. Devillé C, Gharbi M, Dandriofosse G, Peulen O. Study on the effects of laminarin, a polysaccharide from seaweed, on gut characteristics. *J Sci Food Agric*. 2007;87:1717–1725.
87. Lahaye M, Robic A. Structure and functional properties of ulvan, a polysaccharide from green seaweeds. *Biomacromolecules*. 2007;8:1765–1774.
88. Lahaye M, Rochas C. Chemical structure and physico-chemical properties of agar. *Hydrobiologia*. 1991;221:137–148.
89. Li B, Lu F, Wei X, Zhao R. Fucoidan: structure and bioactivity. *Molecules*. 2008;13:1671–1695.
90. Usov AI. Polysaccharides of the red algae. *Adv Carbohydr Chem Biochem*. 2011;65:115–217.
91. Office of Nutrition and Food Labeling, Center for Food Safety and Applied Nutrition. *Science Review of Isolated and Synthetic Non-Digestible Carbohydrates*. College Park, MD: US Department of Health and Human Services, US Food and Drug Administration; 2016.
92. EFSA Panel on Food Additives and Nutrient Sources Added to Food. Scientific opinion on the re-evaluation of agar (E 406) as a food additive. *EFSA J*. 2016;14:4645. doi:10.2903/j.efsa.2016.4645
93. EFSA Panel on Food Additives and Nutrient Sources Added to Food. Scientific opinion on the re-evaluation of alginic acid and its sodium, potassium, ammonium and calcium salts (E 400–E 404) as food additives. *EFSA J*. 2017;15:5049. doi:10.2903/j.efsa.2017.5049
94. European Commission. Commission Implementing Regulation (EU) 2017/2470 of 20 December 2017 establishing the Union list of novel foods in accordance with Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods (Text with EEA relevance). https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJL_2017.351.01.0072.01.ENG. Published December 20, 2017. Accessed December 20, 2018.

95. Burges Watson D. Public health and carrageenan regulation: a review and analysis. In: Borowitzka MA, Critchley AT, Kraan S, Peters A, Sjøtun K, Notoya M, eds. *Nineteenth International Seaweed Symposium: Proceedings of the 19th International Seaweed Symposium*. Kobe, Japan: International Seaweed Association; 2009:55–63.
96. El Khoury D, Goff HD, Anderson GH. The role of alginates in regulation of food intake and glycemia: a gastroenterological perspective. *Crit Rev Food Sci Nutr*. 2015;55:1406–1424.
97. Chater PJ, Wilcox M, Cherry P, et al. Inhibitory activity of extracts of Hebridean brown seaweeds on lipase activity. *J Appl Phycol*. 2016;28:1303–1313.
98. Peters HP, Koppert RJ, Boers HM, et al. Dose-dependent suppression of hunger by a specific alginate in a low-viscosity drink formulation. *Obesity (Silver Spring)*. 2011;19:1171–1176.
99. Hall AC, Fairclough AC, Mahadevan K, Paxman JR. *Ascophyllum nodosum* enriched bread reduces subsequent energy intake with no effect on postprandial glucose and cholesterol in healthy, overweight males. A pilot study. *Appetite*. 2012;58:379–386.
100. Georg Jensen M, Kristensen M, Belza A, et al. Acute effect of alginate-based pre-load on satiety feelings, energy intake, and gastric emptying rate in healthy subjects. *Obesity (Silver Spring)*. 2012;20:1851–1858.
101. Paxman JR, Richardson JC, Dettmar PW, Corfe BM. Daily ingestion of alginate reduces energy intake in free-living subjects. *Appetite*. 2008;51:713–719.
102. Odunsi ST, Vazquez-Roque MI, Camilleri M, et al. Effect of alginate on satiation, appetite, gastric function, and selected gut satiety hormones in overweight and obesity. *Obesity (Silver Spring)*. 2010;18:1579–1584.
103. Torsdottir I, Alpsten M, Holm G, et al. A small dose of soluble alginate-fiber affects postprandial glycemia and gastric emptying in humans with diabetes. *J Nutr*. 1991;121:795–799.
104. Office of Food Additive Safety, US Food and Drug Administration. GRAS notification for fucoidan concentrate from *Fucus vesiculosus*. College Park, MD: Office of Food Additive Safety, US Food and Drug Administration; 2016. GRAS Notice No. 661.
105. Kim MJ, Jeon J, Lee JS. Fucoidan prevents high-fat diet-induced obesity in animals by suppression of fat accumulation. *Phytother Res*. 2014;28:137–143.
106. Lim SJ, Mustapha WAW, Maskat MY. Seaweed tea: fucoidan-rich functional food product development from Malaysian brown seaweed, *Sargassum binderi*. *Sains Malays*. 2017;46:1573–1579.
107. Hernandez-Corona DM, Martinez-Abundis E, Gonzalez-Ortiz M. Effect of fucoidan administration on insulin secretion and insulin resistance in overweight or obese adults. *J Med Food*. 2014;17:830–832.
108. Jeon SM, Kim HJ, Woo MN, et al. Fucosanthin-rich seaweed extract suppresses body weight gain and improves lipid metabolism in high-fat-fed C57BL/6J mice. *Biotechnol J*. 2010;5:961–969.
109. Wang J, Jin W, Zhang W, et al. Hypoglycemic property of acidic polysaccharide extracted from *Saccharina japonica* and its potential mechanism. *Carbohydr Polym*. 2013;95:143–147.
110. Yokota T, Nomura K, Nagashima M, Kamimura N. Fucoidan alleviates high-fat diet-induced dyslipidemia and atherosclerosis in ApoEsh1 mice deficient in apolipoprotein E expression. *J Nutr Biochem*. 2016;32:46–54.
111. Lin HV, Tsou YC, Chen YT, et al. Effects of low-molecular-weight fucoidan and high stability fucosanthin on glucose homeostasis, lipid metabolism, and liver function in a mouse model of type II diabetes. *Mar Drugs*. 2017;15:113. doi:10.3390/md15040113
112. Irmeh MR, Fitton JH, Lowenthal RM. Pilot clinical study to evaluate the anticoagulant activity of fucoidan. *Blood Coagul Fibrinolysis*. 2009;20:607–610.
113. Dockal M, Till S, Knappe S, et al. Anticoagulant activity and mechanism of non-anticoagulant sulfated polysaccharides [abstract]. *Blood*. 2011;118:1208. <http://www.bloodjournal.org/content/118/21/1208>. Accessed January 15, 2019.
114. Church FC, Meade JB, Treanor RE, Whinna HC. Antithrombin activity of fucoidan. The interaction of fucoidan with heparin cofactor II, antithrombin III, and thrombin. *J Biol Chem*. 1989;264:3618–3623.
115. Ren R, Azuma Y, Ojima T, et al. Modulation of platelet aggregation-related eicosanoid production by dietary F-fucoidan from brown alga *Laminaria japonica* in human subjects. *Br J Nutr*. 2013;110:880–890.
116. Nagamine T, Nakazato K, Tomioka S, et al. Intestinal absorption of fucoidan extracted from the brown seaweed, *Cladosiphon okamuranus*. *Mar Drugs*. 2014;13:48–64.
117. Atashrazm F, Lowenthal RM, Woods GM, et al. Fucoidan and cancer: a multifunctional molecule with anti-tumor potential. *Mar Drugs*. 2015;13:2327–2346.
118. Tsai HL, Tai CJ, Huang CW, et al. Efficacy of low-molecular-weight fucoidan as a supplemental therapy in metastatic colorectal cancer patients: a double-blind randomized controlled trial. *Mar Drugs*. 2017;15:122. doi:10.3390/md15040122
119. UK National Archives. The Cancer Act 1939 as amended by The Medicines Act 1968, The Criminal Procedure (Scotland) Act 1975, The Statute Law (Repeals) Act 1986, and The Legislative Reform (Local Authority Consent Requirements) (England and Wales) Order 2008. UK Public General Act No. 19390013. <https://www.legislation.gov.uk/ukpga/Geo6/2-3/13/section/4>. Published March 29, 1939. Accessed December 20, 2018.
120. UK National Archives. The Consumer Protection from Unfair Trading Regulations 2008. Legislation Statutory Instruments No. 1277. http://www.legislation.gov.uk/uksi/2008/1277/pdfs/uksi_20081277_en.pdf. Enacted May 8, 2008. Accessed December 20, 2018.
121. Michel C, Lahaye M, Bonnet C, et al. In vitro fermentation by human faecal bacteria of total and purified dietary fibres from brown seaweeds. *Br J Nutr*. 1996;75:263–280.
122. Ramnani P, Chittarri R, Tuohy K, et al. In vitro fermentation and prebiotic potential of novel low molecular weight polysaccharides derived from agar and alginate seaweeds. *Anaerobe*. 2012;18:1–6.
123. Bai S, Chen H, Zhu L, et al. Comparative study on the in vitro effects of *Pseudomonas aeruginosa* and seaweed alginates on human gut microbiota. *PLoS One*. 2017;12:e0171576. doi:10.1371/journal.pone.0171576
124. Bajury DM, Rawi MH, Sazali IH, et al. Prebiotic evaluation of red seaweed (*Kappaphycus alvarezii*) using in vitro colon model. *Int J Food Sci Nutr*. 2017;68:821–828.
125. Fu X, Cao C, Ren B, et al. Structural characterization and in vitro fermentation of a novel polysaccharide from *Sargassum thunbergii* and its impact on gut microbiota. *Carbohydr Polym*. 2018;183:230–239.
126. Liu J, Kandasamy S, Zhang J, et al. Prebiotic effects of diet supplemented with the cultivated red seaweed *Chondrus crispus* or with fructo-oligo-saccharide on host immunity, colonic microbiota and gut microbial metabolites. *BMC Complement Altern Med*. 2015;15:279.
127. Nguyen SG, Kim J, Guevarra RB, et al. Laminarin favorably modulates gut microbiota in mice fed a high-fat diet. *Food Funct*. 2016;7:4193–4201.
128. Yamada Y, Miyoshi T, Tanada S, Imaki M. Digestibility and energy availability of Wakame (*Undaria pinnatifida*) seaweed in Japanese. *Nihon Eiseigaku Zasshi*. 1991;46:788–794.
129. Marinho GS, Holdt SL, Jacobsen C, Angelidaki I. Lipids and composition of fatty acids of *Saccharina latissima* cultivated year-round in integrated multi-trophic aquaculture. *Mar Drugs*. 2015;13:4357–4374.
130. EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific opinion on dietary reference values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. *EFSA J*. 2010;8:1461. doi:10.2903/j.efsa.2010.1461
131. Hunter PM, Hegele RA. Functional foods and dietary supplements for the management of dyslipidaemia. *Nat Rev Endocrinol*. 2017;13:278–288.
132. Okada T, Mizuno Y, Sibayama S, et al. Antiobesity effects of *Undaria* lipid capsules prepared with scallop phospholipids. *J Food Sci*. 2011;76:H2–H6.
133. Robertson RC, Guiheneuf F, Bahar B, et al. The anti-inflammatory effect of algae-derived lipid extracts on lipopolysaccharide (LPS)-stimulated human THP-1 macrophages. *Mar Drugs*. 2015;13:5402–5424.
134. da Costa E, Melo T, Moreira ASP, et al. Valorization of lipids from *Gracilaria* sp through lipidomics and decoding of antiproliferative and anti-inflammatory activity. *Mar Drugs*. 2017;15:62. doi:10.3390/md15030062
135. Wang R, Paul VJ, Luesch H. Seaweed extracts and unsaturated fatty acid constituents from the green alga *Ulva lactuca* as activators of the cytoprotective Nrf2-ARE pathway. *Free Radic Biol Med*. 2013;57:141–153.
136. Heffernan N, Brunton NP, FitzGerald RJ, Smyth TJ. Profiling of the molecular weight and structural isomer abundance of macroalgae-derived phlorotannins. *Mar Drugs*. 2015;13:509–528.
137. Hwang E-S, Thi ND. Effects of extraction and processing methods on antioxidant compound contents and radical scavenging activities of laver (*Porphyra tenera*). *Prev Nutr Food Sci*. 2014;19:40–48.
138. Murugan AC, Karim MR, Yusoff MBM, et al. New insights into seaweed polyphenols on glucose homeostasis. *Pharm Biol*. 2015;53:1087–1097.
139. Wan-Loy C, Siew-Moi P. Marine algae as a potential source for anti-obesity agents. *Mar Drugs*. 2016;14:222. doi:10.3390/md14120222
140. Fernando IPS, Kim M, Son KT, et al. Antioxidant activity of marine algal polyphenolic compounds: a mechanistic approach. *J Med Food*. 2016;19:615–628.
141. Yang HC, Zeng MY, Dong SY, et al. Anti-proliferative activity of phlorotannin extracts from brown algae *Laminaria japonica* Aresch. *Chin J Ocean Limnol*. 2010;28:122–130.
142. Farasat M, Khavari-Nejad RA, Nabavi SMB, Namjooyan F. Antioxidant activity, total phenolics and flavonoid contents of some edible green seaweeds from northern coasts of the Persian Gulf. *Iran J Pharm Res*. 2014;13:163–170.
143. Machu L, Misurcova L, Ambrozova JV, et al. Phenolic content and antioxidant capacity in algal food products. *Molecules*. 2015;20:1118–1133.
144. Bohn T. Dietary factors affecting polyphenol bioavailability. *Nutr Rev*. 2014;72:429–452.
145. Corona G, Ji Y, Anegoonlap P, et al. Gastrointestinal modifications and bioavailability of brown seaweed phlorotannins and effects on inflammatory markers. *Br J Nutr*. 2016;115:1240–1253.
146. Motshakeri M, Ebrahimi M, Goh YM, et al. *Sargassum polycystum* reduces hyperglycaemia, dyslipidaemia and oxidative stress via increasing insulin sensitivity in a rat model of type 2 diabetes. *J Sci Food Agric*. 2013;93:1772–1778.
147. Motshakeri M, Ebrahimi M, Goh YM, et al. Effects of brown seaweed (*Sargassum polycystum*) extracts on kidney, liver, and pancreas of type 2 diabetic rat model.

- Evid-Based Complement Alternat Med.* 2014;2014:379407. doi: 10.1155/2014/379407
148. Zhang JZ, Tiller C, Shen JK, et al. Antidiabetic properties of polysaccharide- and polyphenolic-enriched fractions from the brown seaweed *Ascophyllum nodosum*. *Can J Physiol Pharmacol.* 2007;85:1116–1123.
 149. Iwai K. Antidiabetic and antioxidant effects of polyphenols in brown alga *Ecklonia stolonifera* in genetically diabetic KK-A^y mice. *Plant Foods Hum Nutr.* 2008;63:163–169.
 150. Kim MJ, Kim HK. Insulinotropic and hypolipidemic effects of *Ecklonia cava* in streptozotocin-induced diabetic mice. *Asian Pac J Trop Med.* 2012;5:374–379.
 151. Kang MC, Kang N, Kim SY, et al. Popular edible seaweed, *Gelidium amansii* prevents against diet-induced obesity. *Food Chem Toxicol.* 2016;90:181–187.
 152. Pantidos N, Boath A, Lund V, et al. Phenolic-rich extracts from the edible seaweed, *Ascophyllum nodosum*, inhibit α -amylase and α -glucosidase: potential anti-hyperglycemic effects. *J Funct Foods.* 2014;10:201–209.
 153. Austin C, Stewart D, Allwood JW, McDougall GJ. Extracts from the edible seaweed, *Ascophyllum nodosum*, inhibit lipase activity *in vitro*: contributions of phenolic and polysaccharide components. *Food Funct.* 2018;9:502–510.
 154. Paradis ME, Couture P, Lamarche B. A randomised crossover placebo-controlled trial investigating the effect of brown seaweed (*Ascophyllum nodosum* and *Fucus vesiculosus*) on postchallenge plasma glucose and insulin levels in men and women. *Appl Physiol Nutr Metab.* 2011;36:913–919.
 155. Murray M, Dordevic AL, Ryan L, Bonham MP. The impact of a single dose of a polyphenol-rich seaweed extract on postprandial glycaemic control in healthy adults: a randomised cross-over trial. *Nutrients.* 2018;10:270. doi:10.3390/nu10030270
 156. Lee DH, Park MY, Shim BJ, et al. Effects of *Ecklonia cava* polyphenol in individuals with hypercholesterolemia: a pilot study. *J Med Food.* 2012;15:1038–1044.
 157. Ko SC, Lee M, Lee JH, et al. Dieckol, a phlorotannin isolated from a brown seaweed, *Ecklonia cava*, inhibits adipogenesis through AMP-activated protein kinase (AMPK) activation in 3T3-L1 preadipocytes. *Environ Toxicol Phar.* 2013;36:1253–1260.
 158. Murray M, Dordevic AL, Bonham MP, Ryan L. Do marine algal polyphenols have antidiabetic, antihyperlipidemic or anti-inflammatory effects in humans? A systematic review. *Crit Rev Food Sci Nutr.* 2018;58:2039–2054.
 159. EFSA Panel on Dietetic Products, Nutrition and Allergies. Safety of *Ecklonia cava* phlorotannins as a novel food pursuant to Regulation (EC) No 258/97. *EFSA J.* 2017;15:5003. doi:10.2903/j.efsa.2017.5003
 160. Gall EA, Lelchat F, Hupel M, et al. Extraction and purification of phlorotannins from brown algae. In: Stengel DB, Connan S, eds. *Natural Products from Marine Algae: Methods and Protocols*. 1st ed. New York, NY: Springer Science+Business Media; 2015:131–143.
 161. Yoon M, Kim JS, Um MY, et al. Extraction optimization for phlorotannin recovery from the edible brown seaweed *Ecklonia cava*. *J Aquat Food Prod T.* 2017;26:801–810.
 162. Li YJ, Fu XT, Duan DL, et al. Extraction and Identification of phlorotannins from the brown alga, *Sargassum fusiforme* (Harvey) Setchell. *Mar Drugs.* 2017;15:49. doi:10.3390/md15020049
 163. Christaki E, Bonos E, Giannenas I, Florou-Paneri P. Functional properties of carotenoids originating from algae. *J Sci Food Agric.* 2013;93:5–11.
 164. Mikami K, Hosokawa M. Biosynthetic pathway and health benefits of fucoxanthin, an algae-specific xanthophyll in brown seaweeds. *Int J Mol Sci.* 2013;14:13763–13781.
 165. Sellimi S, Ksouda G, Benslim A, et al. Enhancing colour and oxidative stabilities of reduced-nitrite turkey meat sausages during refrigerated storage using fucoxanthin purified from the Tunisian seaweed *Cystoseira barbata*. *Food Chem Toxicol.* 2017;107:620–629.
 166. Harris RBS. Direct and indirect effects of leptin on adipocyte metabolism. *Biochim Biophys Acta.* 2014;1842:414–423.
 167. Nagappan H, Pee PP, Kee SHY, et al. Malaysian brown seaweeds *Sargassum siliquosum* and *Sargassum polycystum*: low density lipoprotein (LDL) oxidation, angiotensin converting enzyme (ACE), α -amylase, and α -glucosidase inhibition activities. *Food Res Int.* 2017;99:950–958.
 168. Maeda H, Tsukui T, Sashima T, et al. Seaweed carotenoid, fucoxanthin, as a multi-functional nutrient. *Asia Pac J Clin Nutr.* 2008;17:196–199.
 169. Muradian K, Vaiserman A, Min KJ, Fraifeld VE. Fucoxanthin and lipid metabolism: a minireview. *Nutr Metab Cardiovasc Dis.* 2015;25:891–897.
 170. Beppe F, Hosokawa M, Niwano Y, Miyashita K. Effects of dietary fucoxanthin on cholesterol metabolism in diabetic/obese KK-Ay mice. *Lipids Health Dis.* 2012;11:112. doi:10.1186/1476-511X-11-112
 171. Hitoe SS. H. Seaweed fucoxanthin supplementation improves obesity parameters in mild obese Japanese subjects. *Funct Foods Health Dis.* 2017;7:246–262.
 172. Abidov M, Ramazanov Z, Seifulla R, Grachev S. The effects of XanthigenTM in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat. *Diabetes Obes Metab.* 2010;12:72–81.
 173. Owen EC. The carotene, carotenoid and chlorophyll contents of some Scottish seaweeds. *J Sci Food Agric.* 1954;5:449–453.
 174. Bjørnland T, Aguilar-Martinez M. Carotenoids in red algae. *Phytochemistry.* 1976;15:291–296.
 175. Takaichi S. Carotenoids in algae: distributions, biosyntheses and functions. *Mar Drugs.* 2011;9:1101–1118.
 176. Desideri D, Cantaluppi C, Ceccotto F, et al. Essential and toxic elements in seaweeds for human consumption. *J Toxicol Environ Health A.* 2016;79:112–122.
 177. Lim YS, Lee SW, Tserendejid Z, et al. Prevalence of osteoporosis according to nutrient and food group intake levels in Korean postmenopausal women: using the 2010 Korea National Health and Nutrition Examination Survey Data. *Nutr Res Pract.* 2015;9:539–546.
 178. Dawczynski C, Schaefer U, Leiterer M, Jahreis G. Nutritional and toxicological importance of macro, trace, and ultra-trace elements in algae food products. *J Agric Food Chem.* 2007;55:10470–10475.
 179. Garcia-Casal MN, Ramirez J, Leets I, et al. Antioxidant capacity, polyphenol content and iron bioavailability from algae (*Ulva* sp., *Sargassum* sp. and *Porphyra* sp.) in human subjects. *Br J Nutr.* 2009;101:79–85.
 180. Garcia-Casal MN, Pereira AC, Leets I, et al. High iron content and bioavailability in humans from four species of marine algae. *J Nutr.* 2007;137:2691–2695.
 181. Nakamura E, Yokota H, Matsui T. The *in vitro* digestibility and absorption of magnesium in some edible seaweeds. *J Sci Food Agric.* 2012;92:2305–2309.
 182. European Parliament, Council of the European Union. Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC and Commission Regulation (EC) No 608/2004 (Text with EEA relevance). <https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32011R1169&from=EN>. Published November 22, 2011. Accessed December 20, 2018.
 183. Watanabe F, Takenaka S, Katsura H, et al. Dried green and purple lavers (nori) contain substantial amounts of biologically active vitamin B₁₂ but less of dietary iodine relative to other edible seaweeds. *J Agric Food Chem.* 1999;47:2341–2343.
 184. Miyamoto E, Yabuta Y, Kwak CS, et al. Characterization of vitamin B₁₂ compounds from Korean purple laver (*Porphyra* sp.) products. *J Agric Food Chem.* 2009;57:2793–2796.
 185. Pawlak R, Lester SE, Babatunde T. The prevalence of cobalamin deficiency among vegetarians assessed by serum vitamin B12: a review of literature. *Eur J Clin Nutr.* 2014;68:541–548.
 186. Suzuki H. Serum vitamin B₁₂ levels in young vegans who eat brown rice. *J Nutr Sci Vitaminol (Tokyo).* 1995;41:587–594.
 187. Watanabe F, Takenaka S, Kittaka-Katsura H, et al. Characterization and bioavailability of vitamin B12-compounds from edible algae. *J Nutr Sci Vitaminol (Tokyo).* 2002;48:325–331.
 188. Yamada K, Yamada Y, Fukuda M, Yamada S. Bioavailability of dried asakusanori (*Porphyra tenera*) as a source of cobalamin (vitamin B₁₂). *Int J Vitam Nutr Res.* 1999;69:412–418.
 189. Food Standards Agency. *Assessment of dietary sodium for adults (19 to 64 years) in Northern Ireland*. Belfast, Northern Ireland: Food Standards Agency Northern Ireland; 2016.
 190. Food Standards Agency, Government of the United Kingdom. Salt reduction targets for 2017. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/604338/Salt_reduction_targets_for_2017.pdf. Published March 30, 2017. Accessed December 20, 2018.
 191. Zava TT, Zava DT. Assessment of Japanese iodine intake based on seaweed consumption in Japan: a literature-based analysis. *Thyroid Res.* 2011;4:14. doi:10.1186/1756-6614-4-14
 192. EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific opinion on dietary reference values for iodine. *EFSA J.* 2014;12:3660. doi:10.2903/j.efsa.2014.3660
 193. Joint Food and Agriculture Organization of the United Nations/World Health Organization Expert Committee on Food Additives. *Evaluation of Certain Food Additives and Contaminants: Seventy-Third Report of the Joint FAO/WHO Expert Committee on Food Additives*. Geneva: WHO Press; 2011. WHO Technical Report Series 960.
 194. Michikawa T, Inoue M, Shimazu T, et al. Seaweed consumption and the risk of thyroid cancer in women: the Japan Public Health Center-based Prospective Study. *Eur J Cancer Prev.* 2012;21:254–260.
 195. Wang CC, Yatsuya H, Li YY, et al. Prospective study of seaweed consumption and thyroid cancer incidence in women: the Japan Collaborative Cohort Study. *Eur J Cancer Prev.* 2016;25:239–245.
 196. Konno N, Makita H, Yuri K, et al. Association between dietary iodine intake and prevalence of subclinical hypothyroidism in the coastal regions of Japan. *J Clin Endocrinol Metab.* 1994;78:393–397.
 197. Eliason BC. Transient hyperthyroidism in a patient taking dietary supplements containing kelp. *J Am Board Fam Pract.* 1998;11:478–480.
 198. Mussig K, Thamer C, Bares R, et al. Iodine-induced thyrotoxicosis after ingestion of kelp-containing tea. *J Gen Intern Med.* 2006;21:C11–C14.

199. Zimmermann M, Delange F. Iodine supplementation of pregnant women in Europe: a review and recommendations. *Eur J Clin Nutr*. 2004;58:979–984.
200. Bath SC, Hill S, Infante HG, et al. Iodine concentration of milk-alternative drinks available in the UK in comparison with cows' milk. *Br J Nutr*. 2017;118:525–532.
201. Llop S, Lopez-Espinosa MJ, Murcia M, et al. Synergism between exposure to mercury and use of iodine supplements on thyroid hormones in pregnant women. *Environ Res*. 2015;138:298–305.
202. Teas J, Pino S, Critchley A, Braverman LE. Variability of iodine content in common commercially available edible seaweeds. *Thyroid*. 2004;14:836–841.
203. Dominguez-Gonzalez MR, Chiochetti GM, Herbello-Hermelo P, et al. Evaluation of iodine bioavailability in seaweed using in vitro methods. *J Agric Food Chem*. 2017;65:8435–8442.
204. Nitschke U, Stengel DB. A new HPLC method for the detection of iodine applied to natural samples of edible seaweeds and commercial seaweed food products. *Food Chem*. 2015;172:326–334.
205. Hou XL, Yan XJ, Chai CF. Chemical species of iodine in some seaweeds II. Iodine-bound biological macromolecules. *J Radioanal Nucl Chem*. 2000;245:461–467.
206. Nathans D, Tapley DF, Ross JE. Intestinal transport of amino acids studied in vitro with L-[¹³¹I]moniodotyrosine. *Biochim Biophys Acta*. 1960;41:271–282.
207. Nicola JP, Basquin C, Portulano C, et al. The Na⁺/I[−] symporter mediates active iodide uptake in the intestine. *Am J Physiol Cell Physiol*. 2009;296:C654–C662.
208. Nicola JP, Reyna-Neyra A, Carrasco N, Masini-Repiso AM. Dietary iodide controls its own absorption through post-transcriptional regulation of the intestinal Na⁺/I[−] symporter. *J Physiol*. 2012;590:6013–6026.
209. Aquaron R, Delange F, Marchal P, et al. Bioavailability of seaweed iodine in human beings. *Cell Mol Biol (Noisy-le-Grand)*. 2002;48:563–569.
210. Lightowler HJ, Davies GJ. Iodine intake and iodine deficiency in vegans as assessed by the duplicate-portion technique and urinary iodine excretion. *Br J Nutr*. 1998;80:529–535.
211. Remer T, Neubert A, Manz F. Increased risk of iodine deficiency with vegetarian nutrition. *Br J Nutr*. 1999;84:45–49.
212. Krajcovicova-Kudlackova M, Buckova K, Klimes I, Sebkova E. Iodine deficiency in vegetarians and vegans. *Ann Nutr Metab*. 2003;47:183–185.
213. Miyai K, Tokushige T, Kondo M, Grp IR. Suppression of thyroid function during ingestion of seaweed “Kombu” (*Laminaria japonica*) in normal Japanese adults. *Endocr J*. 2008;55:1103–1108.
214. Clark CD, Bassett B, Burge MR. Effects of kelp supplementation on thyroid function in euthyroid subjects. *Endocr Pract*. 2003;9:363–369.
215. Combet E, Ma ZF, Cousins F, et al. Low-level seaweed supplementation improves iodine status in iodine-insufficient women. *Br J Nutr*. 2014;112:753–761.
216. Nitschke U, Stengel DB. Quantification of iodine loss in edible Irish seaweeds during processing. *J Appl Phycol*. 2016;28:3527–3533.
217. Katagiri R, Asakura K, Uechi K, et al. Iodine excretion in 24-hour urine collection and its dietary determinants in healthy Japanese adults. *J Epidemiol*. 2016;26:613–621.
218. Phaneuf D, Cote I, Dumas P, et al. Evaluation of the contamination of marine algae (seaweed) from the St. Lawrence River and likely to be consumed by humans. *Environ Res*. 1999;80(2 pt 2):S175–S182.
219. Caliceti M, Argese E, Sfriso A, Pavoni B. Heavy metal contamination in the seaweeds of the Venice lagoon. *Chemosphere*. 2002;47:443–454.
220. Burger J, Gochfeld M, Jeitner C, et al. Lead (Pb) in biota and perceptions of Pb exposure at a recently designated superfund beach site in New Jersey. *J Toxicol Environ Health*. 2012;75:272–287.
221. Hwang YO, Park SG, Park GY, et al. Total arsenic, mercury, lead, and cadmium contents in edible dried seaweed in Korea. *Food Addit Contam Part B Surveill*. 2010;3:7–13.
222. Giusti L. Heavy metal contamination of brown seaweed and sediments from the UK coastline between the Wear river and the Tees river. *Environ Int*. 2001;26:275–286.
223. Murphy V, Hughes H, McLoughlin P. Cu(II) binding by dried biomass of red, green and brown macroalgae. *Water Res*. 2007;41:731–740.
224. Jarvis TA, Bielmyer-Fraser GK. Accumulation and effects of metal mixtures in two seaweed species. *Comp Biochem Physiol C Toxicol Pharmacol*. 2015;171:28–33.
225. Zhao Y, Shang D, Ning J, et al. Arsenic and cadmium in the marine macroalgae (*Porphyra yezoensis* and *Laminaria japonica*)—forms and concentrations. *Chem Speciation Bioavailability*. 2012;24:197–203.
226. Park S, Lee BK. Strong positive associations between seafood, vegetables, and alcohol with blood mercury and urinary arsenic levels in the Korean adult population. *Arch Environ Contam Toxicol*. 2013;64:160–170.
227. Pack EC, Lee SH, Kim CH, et al. Effects of environmental temperature change on mercury absorption in aquatic organisms with respect to climate warming. *J Toxicol Environ Health*. 2014;77:1477–1490.
228. Squadrone S, Brizio P, Battuello M, et al. A first report of rare earth elements in northwestern Mediterranean seaweeds. *Mar Pollut Bull*. 2017;122:236–242.
229. Koedrith P, Kim H, Weon JI, Seo YR. Toxicogenomic approaches for understanding molecular mechanisms of heavy metal mutagenicity and carcinogenicity. *Int J Hyg Environ Health*. 2013;216:587–598.
230. Caserta D, Graziano A, Lo Monte G, et al. Heavy metals and placental fetal-maternal barrier: a mini-review on the major concerns. *Eur Rev Med Pharmacol Sci*. 2013;17:2198–2206.
231. Taylor CM, Golding J, Emond AM. Lead, cadmium and mercury levels in pregnancy: the need for international consensus on levels of concern. *J Dev Orig Health Dis*. 2014;5:16–30.
232. Feldmann J, Krupp EM. Critical review or scientific opinion paper: arsenosugars—a class of benign arsenic species or justification for developing partly speciated arsenic fractionation in foodstuffs?. *Anal Bioanal Chem*. 2011;399:1735–1741.
233. Arslan B, Djamgoz MBA, Akun E. ARSENIC: a review on exposure pathways, accumulation, mobility and transmission into the human food chain. *Rev Environ Contam Toxicol*. 2017;243:27–51.
234. Khan F, Momtaz S, Niaz K, et al. Epigenetic mechanisms underlying the toxic effects associated with arsenic exposure and the development of diabetes. *Food Chem Toxicol*. 2017;107:406–417.
235. Taylor VF, Li ZG, Sayarath V, et al. Distinct arsenic metabolites following seaweed consumption in humans [published correction appears in Sci Rep. 2018;8:4145. doi:10.1038/s41598-018-22625-x]. *Sci Rep*. 2017;7:3920. doi:10.1038/s41598-017-03883-7
236. Van Hulle M, Zhang C, Schotte B, et al. Identification of some arsenic species in human urine and blood after ingestion of Chinese seaweed *Laminaria*. *J Anal At Spectrom*. 2004;19:58–64.
237. Francesconi KA, Tanggaard R, McKenzie CJ, et al. Arsenic metabolites in human urine after ingestion of an arsenosugar. *Clin Chem*. 2002;48:92–101.
238. Andrewes P, Demarini DM, Funasaka K, et al. Do arsenosugars pose a risk to human health? The comparative toxicities of a trivalent and pentavalent arsenosugar. *Environ Sci Technol*. 2004;38:4140–4148.
239. Ronan JM, Stengel DB, Raab A, et al. High proportions of inorganic arsenic in *Laminaria digitata* but not in *Asophyllum nodosum* samples from Ireland. *Chemosphere*. 2017;186:17–23.
240. Taylor VF, Jackson BP. Concentrations and speciation of arsenic in New England seaweed species harvested for food and agriculture. *Chemosphere*. 2016;163:6–13.
241. French Agency for Food, Environmental and Occupational Health & Safety. Opinion of the French Food Safety Agency on the recommended maximum inorganic arsenic content of laminaria and consumption of these seaweeds in light of their high iodine content. <https://www.anses.fr/en/content/opinion-french-food-safety-agency-recommended-maximum-inorganic-arsenic-content-laminaria>. Published April 17, 2009. Accessed February 6, 2018.
242. Food Standards Australia New Zealand. Survey of inorganic arsenic in seaweed and seaweed-containing products available in Australia. <http://www.foodstandards.gov.au/science/surveillance/Pages/surveyofinorganics5773.aspx>. Published January 2013. Accessed February 7, 2018.
243. Almela C, Clemente MJ, Velez D, Montoro R. Total arsenic, inorganic arsenic, lead and cadmium contents in edible seaweed sold in Spain. *Food Chem Toxicol*. 2006;44:1901–1908.
244. Risk Assessment Section, Centre for Food Safety, Government of the Hong Kong Special Administrative Region. Risk in brief: hijiki and arsenic. http://www.cfs.gov.hk/english/programme/programme_rafs/programme_rafs_fc_02_08.html. Published February 2011. Accessed February 7, 2018.
245. Food Safety Authority of Ireland. Consumption of hijiki seaweed. https://www.fsai.ie/faq/hijiki_seaweed.html. Last reviewed September 29, 2015. Accessed February 7, 2018.
246. Food Standards Australia New Zealand. *Imported Food Risk Statement: Hijiki Seaweed and Inorganic Arsenic*. Canberra, Australia: Food Standards Australia New Zealand; 2016.
247. Superior Health Council of Belgium. Arsenic and other elements in algae and dietary supplements based on algae. <https://www.health.belgium.be/en/arsenic-and-other-elements-algae-and-dietary-supplements-based-algae-1-april-2015-shc-9149>. Published April 1, 2015. Accessed February 7, 2018.
248. Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment. Annual Report of the Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment. <https://cot.food.gov.uk/sites/default/files/cot/cotsection.pdf>. Published 2004. Accessed February 7, 2018.
249. Yokoi K, Konomi A. Toxicity of so-called edible hijiki seaweed (*Sargassum fusiforme*) containing inorganic arsenic. *Regul Toxicol Pharmacol*. 2012;63:291–297.
250. Rose M, Lewis J, Langford N, et al. Arsenic in seaweed—forms, concentration and dietary exposure. *Food Chem Toxicol*. 2007;45:1263–1267.
251. Zhao YF, Wu JF, Shang DR, et al. Arsenic species in edible seaweeds using in vitro biomimetic digestion determined by high-performance liquid chromatography inductively coupled plasma mass spectrometry. *Int J Food Sci*. 2014;2014:436347. doi:10.1155/2014/436347
252. Laparra JM, Velez D, Montoro R, et al. Estimation of arsenic bioaccessibility in edible seaweed by an in vitro digestion method. *J Agric Food Chem*. 2003;51:6080–6085.
253. Hajeb P, Sloth JJ, Shakibazadeh S, et al. Toxic elements in food: occurrence, binding, and reduction approaches. *Compr Rev Food Sci Food Saf*. 2014;13:457–472.

254. Wei C, Li WH, Zhang C, et al. Safety evaluation of organoarsenical species in edible *Porphyra* from the China Sea. *J Agric Food Chem*. 2003;51:5176–5182.
255. Almela C, Laparra JM, Velez D, et al. Arsenosugars in raw and cooked edible seaweed: characterization and bioaccessibility. *J Agric Food Chem*. 2005;53:7344–7351.
256. Taylor V, Goodale B, Raab A, et al. Human exposure to organic arsenic species from seafood. *Sci Total Environ*. 2017;580:266–282.
257. Mania M, Rebeniak M, Szynal T, et al. Total and inorganic arsenic in fish, seafood and seaweeds—exposure assessment. *Rocz Panstw Zakl Hig*. 2015;66:203–210.
258. Adamse P, Van der Fels-Klerx HJ, de Jong J. Cadmium, lead, mercury and arsenic in animal feed and feed materials—trend analysis of monitoring results. *Food Addit Contam Part A Chem Anal Control Expo Risk Assess*. 2017;34:1298–1311.
259. Castlehouse H, Smith C, Raab A, et al. Biotransformation and accumulation of arsenic in soil amended with seaweed. *Environ Sci Technol*. 2003;37:951–957.
260. Brandon EFA, Janssen PJCM, de Wit-Bos L. Arsenic: bioaccessibility from seaweed and rice, dietary exposure calculations and risk assessment. *Food Addit Contam Part A Chem Anal Control Expo Risk Assess*. 2014;31:1993–2003.
261. Nanri A, Mizoue T, Shimazu T, et al. Dietary patterns and all-cause, cancer, and cardiovascular disease mortality in Japanese men and women: the Japan Public Health Center-based Prospective Study. *PLoS One*. 2017;12. doi:10.1371/journal.pone.0174848
262. Shin A, Lim SY, Sung J, et al. Dietary intake, eating habits, and metabolic syndrome in Korean men. *J Am Diet Assoc*. 2009;109:633–640.
263. Key TJ, Appleby PN, Reeves GK, et al. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. *Lancet Oncol*. 2010;11:530–542.
264. Teas J, Irhimeh MR, Druker S, et al. Serum IGF-1 concentrations change with soy and seaweed supplements in healthy postmenopausal American women. *Nutr Cancer*. 2011;63:743–748.
265. Yang YJ, Nam SJ, Kong G, Kim MK. A case-control study on seaweed consumption and the risk of breast cancer. *Br J Nutr*. 2010;103:1345–1353.
266. Hoshiyama Y, Sasaba T. A case-control study of single and multiple stomach cancers in Saitama Prefecture, Japan. *J Jpn J Cancer Res*. 1992;83:937–943.
267. Hoshiyama Y, Sekine T, Sasaba T. A case-control study of colorectal cancer and its relation to diet, cigarettes, and alcohol consumption in Saitama Prefecture, Japan. *Tohoku J Exp Med*. 1993;171:153–165.
268. Miyake Y, Sasaki S, Ohya Y, et al. Dietary intake of seaweed and minerals and prevalence of allergic rhinitis in Japanese pregnant females: baseline data from the Osaka Maternal and Child Health Study. *Ann Epidemiol*. 2006;16:614–621.
269. Food Standards Australia New Zealand. Advice on brown seaweed for pregnant women; breastfeeding women and children. <http://www.foodstandards.gov.au/consumer/safety/brownseaweed/Pages/default.aspx>. Updated June 2011. Accessed February 7, 2018.
270. Park JH, Jeong HS, Lee JS, et al. First norovirus outbreaks associated with consumption of green seaweed (*Enteromorpha* spp.) in South Korea. *Epidemiol Infect*. 2015;143:515–521.
271. Haddock RL, Cruz OLT. Foodborne intoxication associated with seaweed. *Lancet*. 1991;338:195–196.
272. Yotsu-Yamashita M, Yasumoto T, Yamada S, et al. Identification of polycavernoside A as the causative agent of the fatal food poisoning resulting from ingestion of the red alga *Gracilaria edulis* in the Philippines. *Chem Res Toxicol*. 2004;17:1265–1271.
273. Zhou BF, Stamler J, Dennis B, et al. Nutrient intakes of middle-aged men and women in China, Japan, United Kingdom, and United States in the late 1990s: the INTERMAP study. *J Hum Hypertens*. 2003;17:623–630.
274. Katagiri R, Asakura K, Uechi K, et al. Adequacy of iodine intake in three different Japanese adult dietary patterns: a nationwide study. *Nutr J*. 2015;14. doi:10.1186/s12937-015-0116-y
275. Allsopp P, Crowe W, Bahar B, et al. The effect of consuming *Palmaria palmata*-enriched bread on inflammatory markers, antioxidant status, lipid profile and thyroid function in a randomised placebo-controlled intervention trial in healthy adults. *Eur J Nutr*. 2016;55:1951–1962.